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ABSTRACT
The dopamine transporter (DAT) is a neuronal presynaptic 
transmembrane protein that clears released dopamine (DA) from the synaptic 
space, regulating the neurotransmitter concentration and availability. DAT and 
the related serotonin (SERT) and norepinephrine (NET) transporters belong to 
the SLC6 family of Na+ and Cl' dependent symporters, and are major targets for 
the action of several drugs, including the psychostimulant cocaine. DAT is 
predicted to possess 12 transmembrane spanning domains (TMs), with both N- 
and C-termini located intracellulariy. Extensive research efforts to gain insight on 
the molecular aspects of DAT have been attempted, but the three-dimensional 
arrangement of the protein as well as the molecular mechanisms involved in 
substrate translocation remain undiscovered.
Cocaine and other structurally diverse compounds bind to DAT with high 
affinity and inhibit its transport activity, but their binding site within the protein and 
the mechanism by which they block DA transport remain unclear. Two distinct 
ligand interaction sites at transmembrane domains (TMs) 1-2 and 4-6 have been 
identified using irreversible uptake-blockers. The current studies explore the 
incorporation site of the novel cocaine analogue [125l]MFZ-2-24, which is 
structurally similar to the previously characterized [125I]RTI 82, but the reactive 
azido (Ns) group is differentially positioned within the cocaine pharmacophore.
Trypsin and cyanogen bromide (CNBr) proteolytic maps of [125!]MFZ-2-24
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labeled rat and human DATs, followed by epitope-specific immunoprecipitation 
were used to localize the incorporation site of the ligand to a 13 amino acid 
stretch in Tl , between residues I67 and L80. This highly conserved region 
harbors the functionally essential D79 and residues involved in substrate and 
inhibitor binding. In marked contrast, incorporation of [125I]RTI 82 occurs in TM6, 
demonstrating that differential positioning of the N3 group on the cocaine 
pharmacophore leads to distinct incorporation patterns. This further indicates that 
TMs 1 and 6 are in close proximity three-dimensionally and participate in the 
reversible binding of cocaine to DAT.
CHAPTER I
INTRODUCTION
The Discovery of Chemical Neurotransmission 
Until the end of the 19th century the nerve impulse was believed to 
propagate in an electrical manner, but this concept was not proven to be 
responsible for the transference of information between nerves and their target 
cells. The idea of chemical transmission was initially proposed through studies 
involving the physiological effects of adrenal extracts on a variety of tissues. In 
1904 Elliott reported the actions of adrenaline in sympathetic axons and 
hypothesized that sympathetic nerves communicate chemically with their target 
cells, which contain specific recognition sites for these substances [1 , reviewed in 
2], Between 1920 and 1940 the laboratory of Otto Loewi in Austria studied frog 
hearts and proposed that vagal stimulation is due to the actions of acetylcholine 
and sympathetic stimulation is mediated by adrenaline [reviewed in 2]. However, 
there were many excitatory effects that could not be explained through the 
adrenaline hypothesis, especially in tissue of mammalian origin, and in 1946 Ulf 
von Euler in Sweden was able to demonstrate that noradrenaline was indeed a 
neurotransmitter, and further that it was the main transmitter mediating 
mammalian sympathetic nerve communication [reviewed in 2].
Since then a plethora of information has become available regarding the 
understanding of chemical neurotransmission and its regulation, and many
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chemically diverse compounds have been identified as neurotransmitters in a 
variety of nerve terminals across the peripheral and central nervous systems.
Neurotransmitter molecules are synthesized in the body of the neuron and 
transported through the axon toward the nerve terminal, where they are actively 
packed into storage vesicles that assemble and dock in the active zone. Upon 
nerve stimulation neurotransmitters are secreted into the synaptic space via 
calcium (Ca2+)-mediated exocytosis. The released transmitters bind to their post- 
synaptic receptors and activate them, generating downstream effects that lead to 
propagation of the action potential. Termination of the signaling events is 
accomplished by neurotransmitter enzymatic degradation or reuptake through 
membrane transport proteins. Once inside the cell, transmitters are either 
repackaged into synaptic vesicles or degraded by intracellular enzymes (Figure 
1).
The Characterization of Dopamine as a Central Neurotransmitter 
Dopamine (3,4-dihydroxyphenylethylamine; DA) is the most newly 
discovered catecholaminergic transmitter in the mammalian brain. It is 
synthesized from the essential amino acid tyrosine through a two-step enzymatic 
reaction that involves the actions of tyrosine hydroxylase (TH) and L-aromatic 
amino acid decarboxylase (AADC) (Figure 2).
Until the mid 1950s DA was solely considered a biosynthetic intermediate 
of norepinephrine and epinephrine, widely known sympathetic neurotransmitters. 
It was then when Carlsson and coworkers demonstrated the normal occurrence 
of DA in the brain and suggested that DA was itself a neurotransmitter. These
2
Figure 1. Schematic Diagram of a Dopaminergic Synapse. Newly synthesized 
neurotransmitter molecules (DA, blue dots) are actively packed into synaptic 
vesicles by the vesicular monoamine transporter 2 (VMAT-2, red cylinders). 
Upon arrival of an action potential DA is released via Ca2+'mediated exocytosis 
and binds to pre-synaptic (magenta cylinder) and post-synaptic (light blue 
cylinders) receptors, resulting in modulation of the pre-synaptic neuron and 
propagation of the action potential (green signals), respectively. Termination of 
the dopaminergic signal is achieved through Na+/Cr-coupled DA uptake via the 
action of the dopamine transporter (DAT) (purple trapezoids). Once inside the 
ceil DA is either repackaged into synaptic vesicles or degraded by the 
mitochondrial monoamine oxidase (MAO) (orange oval).
3
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Figure 2. Dopamine Biosynthesis and Degradation Pathway. Biosynthetic 
enzymes are labeled in red and catabolic enzymes are labeled in purple. The 
conversion of Tyrosine to DOPA via Tyrosine Hydroxylase (TH) is the rate- 

















researchers observed depletion of catecholamine stores in rabbit’s adrenal 
gland, heart and brain upon treatment with the antipsychotic reserpine and 
hypothesized that replenishment of the catecholamine stores would revert the 
drug’s effects. After administration of the precursor 3,4-dihydroxyphenylalanine 
(L-DOPA) they found anti-reserpine effects in treated animals and central 
stimulation in untreated animals [3, 4, reviewed in 5]. These findings 
corresponded with the accumulation of DA, but not norepinephrine in the brains 
of these animals, which was, in turn, consistent with DA being a neurotransmitter 
on its own. It was not long until the unique distribution of DA was mapped to the 
basal ganglia [6], and the development of fluorescent techniques in combination 
with pharmacological methods allowed scientists to describe the localization and 
distribution of the monoaminergic pathways in the central nervous system (CNS) 
[7-11].
Dopaminergic Pathways in the Mammalian Central Nervous System
Dopamine is estimated to account for about 80% of the total brain 
catecholamine content. However, the human brain has relatively few 
dopaminergic neurons, about 150,000-200,000 in each hemisphere, mainly 
localized in the midbrain and forebrain. Ultrashort DA systems are comprised by 
retina and olfactory bulb neurons, and intermediate-length systems include the 
Tuberoinfundibular pathway with DA cells that project from the mesobasal 
hypothalamus to the anterior pituitary gland (Figure 3) [12].
The long DA systems have been the most extensively studied 
dopaminergic neurons and are equally divided between the substantia nigra (SN)
7
Figure 3. Dopaminergic Pathways in the Human Brain. DA neurons from the 
substantia nigra project their axons to the striatum, giving rise to the Nigrostriatal 
pathway. DA neurons from the ventral tegmental area extend projections to the 
mesial components of the limbic system, and to the frontal and prefrontal cortices 
to form the Mesolimbic and Mesocortical pathways. The Tuberoinfundibular 
pathway contains DA neurons that extend from the mesobasal hypothalamus to 
the anterior pituitary gland. The physiological functions associated with each of 



















Image modified from Pearson Education/Benjamin Cummings Silverthorn: 
Human Physiology, 3rd Edition, Figure 9.19c, with permission
9
and the ventral tegmental area (VTA) in the basal ganglia. Neurons from the SN 
project their axons into the striatum giving rise to the Nigrostriatal pathway, and 
neurons from the VTA extend to the mesial components of the limbic system 
(nucleus accumbens, amygdala, mesial frontal cortex) and to the frontal and 
prefrontal cortices to originate the Mesolimbic and Mesocortica! pathways (Figure 
3) [12].
The dopaminergic pathways have a key physiological role in a variety of 
processes that include voluntary movement and motor control (Nigrostriatal 
pathway), pleasure and reward (Mesolimbic pathway), motivation and attention 
(Mesocortical Pathway), and prolactin secretion (Tuberoinr'undibular pathway) 
(Figure 3). Malfunctions or dysregulation in these systems have been implicated 
in several neuropsychiatric and behavioral disorders, including Parkinson’s 
disease (PD), Attention Deficit Hyperactivity Disorder (ADHD), depression, 
schizophrenia, and drug abuse.
Dopamine Uptake, Cloning and Localization of the Dopamine Transporter
Termination of acetylcholine signaling was known to be due to enzymatic 
degradation via acetylcholinesterase, but it soon became evident that the 
mechanisms for catecholamine inactivation were distinctively different. Axelrod 
and coworkers discovered that the sympathetic inactivation of norepinephrine 
(NE) was caused by its uptake and accumulation back into the nerve terminal 
[13], and further that these processes were inhibited by the psychoactive 
compounds reserpine, amphetamine (AMPH), imipramine and cocaine [13, 14], 
Subsequent characterization revealed that NE uptake followed Michaelis Menten
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saturation kinetics, was stereospecific for the L-isomer, required sodium (Na+), 
and was temperature dependent, suggesting that an active transport membrane 
carrier system was accountable for this mechanism [15, reviewed in 16 and 17].
In addition, distinctive uptake and pharmacological properties for NE and 
DA were observed in brain regions where these transmitters are commonly 
found. Although cocaine and AMPH exhibited similar inhibition patterns for both 
transmitters, desipramine differentially affected the NE uptake mechanism in the 
cortex in contrast with its minor effects on the striatal dopaminergic uptake 
system [18]. These observations were extended to synaptosomal preparations of 
different brain regions [19], which reinforced the hypothesis that the sites for NE 
and DA uptake are different in noradrenergic- and dopaminergic-specific 
neurons. The use of a variety of psychostimulants allowed further differentiation 
of the catecholaminergic uptake systems in the CNS and the identification of the 
DA-specific uptake site in mouse, rat and human striatal tissue [20-22].
The first indication of an association between DA uptake sites and cocaine 
was originated by Kennedy and Hanbauer [23], They observed a Na+-dependent 
increase in saturable cocaine binding to rat striatal membranes without a change 
in affinity, and a strong correlation between the capability of a variety of drugs to 
inhibit DA uptake and prevent cocaine binding [23, reviewed in 24], Subsequently 
Ritz and coworkers proposed that the cocaine receptor related to substance 
abuse was the site linked to inhibition of DA uptake [25], They reported that 
cocaine and cocaine analogues triggered self-administration in non-human 
primates, and that these substances were potent inhibitors of binding at the
11
transport sites for DA [25, reviewed in 24], Although the inhibitory effects of 
cocaine were shown at nerve terminals for DA, serotonin (5-HT) and NE, this 
group of researchers demonstrated that the inhibition of DA transport was the 
principal mechanism involved with cocaine reinforcing effects. Furthermore, their 
study indicated a non-significant association between cocaine reinforcement and 
either 5-HT or NE inhibition of transport [25].
With these studies it became even clearer that dopamine transporters 
were an essential component of the functional dopaminergic synapse and further 
that they were pharmacologically important as they were affected by a variety of 
substances. In addition, these discoveries sparked deep interest to unveil the 
identity of these proteins and, using the sequence for the y-aminobutyric acid 
(GABA) transporter (GAT) as a probe, four groups of investigators successfully 
cloned the dopamine transporter (DAT) from rat (rDAT) and bovine (bDAT) origin 
[26-29]. Soon after and using the rDAT sequence as a template, the human 
isoform was cloned [30], followed by the mouse and monkey variants [31,32], 
and non-mammalian DATs were identified in the genome of Caenorhabditis 
elegance [33], Drosophila melanogaster [34], Eloria noyesi and Bombix mori [35],
In the human brain, DAT is exclusively targeted to dopaminergic neurons, 
with the highest expression levels comprised to midbrain neurons that arise in 
the SN and VTA. Other regions such as the cortex, amygdala, hypothalamus and 
habenula express lower protein levels. At the subcellular level, DAT localizes to 
the plasma membrane of neuronal perikarya, dendrites, axons, synaptic 
terminals and may also be found in tubulovesicular intracellular structures [36-
12
38], A deeper analysis of DAT localization within the synaptic terminals revealed 
that the protein is distant from the synaptic area of the presynaptic membrane, 
suggesting that clearance of DA happens away from its release site [37], Outside 
the CNS, DAT has been found in several other systems, including stomach, 
pancreas, kidney and lymphocytes [39,40],
Structural Properties of the Dopamine Transporter 
DAT belongs to the SLC6 family of Na+/CI' dependent neurotransmitter 
transporters, also known as neurotransmitter:sodium symporters (NSSs), which 
are secondary active transporters that mediate solute translocation via coupling 
of Na+ and Cl* movement down their electrochemical gradients to upward 
movement of substrate. Other members of this family include the related 
norepinephrine (NET) and serotonin (SERT) transporters as well as carriers for 
GABA, glycine, proline, taurine, betaine, and creatine [reviewed in 41 and 42],
The rDAT and hDAT sequences are the most studied and contain 619 and 
620 residues, respectively. Hydropathy profiling predicts 12 transmembrane 
spanning domains (TMs), mainly composed of a-helical structure, connected by 
extracellular and intracellular loops (ELs and ILs), and the amino- and carboxy- 
terminal tails located intracellularly (Figure 4). Alignment of the mammalian 
DATs’ sequences revealed significant homology among them, with the TMs 
displaying the highest degree of conservation, and the loops and tails the lowest. 
The segment connecting TM3 and TM4, EL2, is the largest loop and represents a 
unique feature found within the SLC6 family.
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Figure 4. Schematic Diagram of the Human DAT (hDAT) Primary Sequence. This 
shows the extracellular side of the protein at the top and the predicted 
transmembrane helices as cylinders. Cysteines 180 and 189 are shown forming 





The presence of a variety of post-translational modifications in DAT 
suggests its function is highly regulated. These modifications are located in 
regions unique to eukaryotic NSSs, particularly EL2 and the N-terminal tail, 
and may thus imply the importance of these domains in regulation of their 
properties, perhaps absent in their prokaryotic counterparts.
Sequence analysis revealed the presence of 3 and 4 potential N- 
glycosylation sites (N-X-S/T) in EL2 of hDAT and rDAT respectively (Figure 4). 
AMinked glycosylation at N181, N188, and N205 in hDAT has been associated 
with proper cell-surface expression, and changes in transport kinetics and in the 
potency of cocaine analogues [43,44]. Two strictly conserved cysteines in DAT 
are found in EL2 (C180 and C189) and have been demonstrated to be disulfide 
bonded and to participate in the appropriate folding of the protein [45,46] (Figure 
4).
The finding of several consensus sites for phophorylation by protein 
kinases in the primary sequence of DAT sparked interest for the role of this 
modification in transporter function [reviewed in 47,48 and 49]. DAT has been 
demonstrated to become phosphorylated in vivo both in constitutive and 
stimulated manners in a cluster of serine residues located in the N-terminal tail 
[50,51]. This modification has been related to mechanisms involving protein 
trafficking, substrate efflux, and protein-protein interactions in DAT, but many 
other mechanistical and regulatory aspects of its function remain unclear 
[reviewed in 49], In addition, DAT undergoes constitutive and stimulated
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modification by single and short-chain ubiquitin complexes on lysines 19, 27 and 
35, located in the N-terminal tail [52], Constitutive ubiquitylation occurs through 
the ubiquitin ligase Parkin, whose mutations lead to deficient removal of 
abnormal DATs and have been associated with PD [53,*4]. Stimulated 
ubiquitylation through the ubiquitin ligase Nedd4-2 triggers movement of DATs 
from the plasma membrane into early and then late endosomes, suggesting 
degradation via the lysosomal pathway [55,56]
Oligomerization
The presence of oligomeric DAT complexes was initially suggested by in 
situ radiation inactivation studies [57], Soon after, chemical cross-linking studies 
provided direct evidence for the existence of DAT homodimers via the TM6 
residue C306 located within a conserved oligomerization motif (GVXXGVXX). In 
addition, the TM4 residue C243 was found to be part of a symmetrical interface 
that resulted in tetramers composed of dimers of dimers [58,59].
The use of co-immunoprecipitation and dominant-negative mutants 
revealed the presence of non-covalent high molecular weight DAT complexes, 
necessary for proper cell surface expression [43]. Additionally, DAT 
oligomerization between wild-type proteins was demonstrated in living cells using 
fluorescence resonance energy transfer (FRET) analysis. The loss of FRET 
signals upon coexpression of wild-type and endoplasmic reticulum export- 
deficient mutants provided supplementary evidence for the importance of 




A number of studies using yeast two-hybrid, co-immunoprecipitation, 
FRET analysis and mass spectroscopy revealed that DATs interact with various 
proteins, mainly via the N- and C-termini [reviewed in 61]. At the N-terminus, 
DAT interacts with protein kinase C (PKC) isoforms and (on, the catalytic 
subunit of protein phosphatase 2A (PP2AC), RACK1 (receptor associated with C- 
kinase) and syntaxin 1A. Interaction partners at the C-terminus include the PDZ 
protein PICK1 (protein interacting with C kinase-1), Hic-5, a-synuclein, and 
CaMKII (calcium-dependent calmodulin kinase-ll). The identification of this wide 
variety of DAT interacting proteins implies that the transporter is present in the 
membrane as a complex, rather than as an isolated entity. Furthermore, these 
protein-protein interactions have been associated with the regulation of several 
aspects of DAT function, including trafficking and transport. The mechanisms by 
which these interactions are integrated and regulated remain unclear and its 
elucidation will provide a better understanding of DAT function in normal and 
pathological states [61].
Functional Properties of DAT
It is well known that the mechanism by which uptake of DA takes place at 
the DAT requires concomitant binding and co-transport of Na+ and Cl' ions, with 
stoichiometry of 1DA:2Na+:1CI' and energy from the plasma membrane Na+/K+ 
ATPase. During the translocation process, DAT is proposed to go through a 
series of conformational movements that result in alternating exposure of the 
central binding site to both the extracellular and intracellular sides of the
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Figure 5. Alternating Access Mechanism for Substrate Translocation. Resting 
DATs are open to the extracellular medium in an “outward” conformation. Upon 
binding of Na+ (red circles), Cl' (yellow circles) and DA (blue circles) the 
transporter undergoes a series of conformational changes that result in an 
“inward" facing conformation, where DATs are closed to the extracellular medium 
and open to the intracellular side of the membrane. After DA and ions are 
released to the intracellular medium DATs reset to the “outward” conformation 
and are ready for a new transport cycle.
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membrane. In this “molecular gating” mechanism, DAT is maintained in a 
conformation “open” to the extracellular side and “closed” to the intracellular side 
of the membrane, where DA and ions bind. Binding triggers a conformational 
change and DAT is now “closed" to the extracellular side and “open” to the 
intraceilular side of the membrane, where DA and ions are released. The 
transporter then resets to the “open” outwardly setting and is ready for a new 
transport cycle (Figure 5) [62,63]. Under the influence of amphetamine (AMPH), 
DAT promotes release of DA from the cytosol to the extracellular environment via 
reverse transport [reviewed in 64]. Additionally, DATs exhibit non-coupled ion 
conductances attributed to non-stoichiometric ion movements across the 
membrane, analogous to ion channels. These channel-like properties of the 
substrate translocation process manifest the presence of “leaking” mechanisms, 
demonstrate that the permeation pathway is not perfectly sealed, and are 
associated with AMPH-induced efflux [65-68].
Prokaryotic Leucine Transporter and Relationship to DAT 
Although many structural and functional characteristics of DAT have been 
elucidated since it was cloned in the eariy 1990s, there is currently limited 
understanding regarding its three dimensional orientation in the plasma 
membrane, the binding sites for DA, ions and uptake blockers, the way the TMs 
rearrange during substrate translocation, and the mechanisms that drive 
blockade of transport by inhibitors. The lack of understanding of the above 
mentioned structural aspects could be attributed mainly to the difficulty in
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isolating and obtaining a crystal structure from eukaryotic members of the SLC6 
family.
A significant advance in this field was provided by studies in the laboratory 
of Eric Gouaux, who reported the high-resolution crystal structure of a bacterial 
homologue of the NSSs [69]. LeuTAa is a Na+-dependent leucine transporter 
isolated from Aquifex aeolicus that shares 20-24% identity with its eukaryotic 
counterparts DAT (20%), SERT (21%) and NET (24%). The LeuTAa crystal 
structure reveals a pseudo two-fold axis arrangement that associates TMs 1-5 
and TMs 6-10, where the leucine and Na+ binding sites are located in a pocket 
comprised of TMs 1, 3, 6 and 8. Interestingly, TMs 1 and 6 are juxtaposed and 
oriented antiparallel. These domains possess the highest amount of conserved 
residues and are not continuous helices. Instead, halfway across the membrane, 
the helices display an extended, non-helical conformation that links the two 
halves of each domain and allows the exposure of main chain atoms for 
coordination of Na+ and leucine binding. The long TMs 3 and 8 also arrange in a 
pseudo two-fold axis, exhibiting a -50° angle with respect to the membrane, and 
possess highly conserved residues that are positioned near the unwound 
portions of TMs 1 and 6. The rest of the TMs surround this central core, and 
function as support structures for the correct positioning of the helices in the 
active site and as the main contau structures with the lipid bilayer. The Na+ and 
leucine binding sites are located contiguously toward the middle portion of the 
protein core. In the LeuT/va crystallized conformation, these sites are obstructed 
from the aqueous environment by both the extracellular and intracellular gates,
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providing evidence that the protein undergoes three possible conformations 
during transport: open to the extracellular medium, closed at both sides, and 
open to the intracellular environment. In addition, LeuTAa was crystallized as a 
dimer whose interface is composed of EL2, and TMs 9 and 12. Despite evidence 
that the eukaryotic NSSs form high-order oligomers, the natural occurrence of 
the LeuTAa dimers or the extent of their functional implications remains unclear.
Despite the low overall sequence similarity of LeuTAa with the mammalian 
transporters of the SLC6 family, the high conservation found within TMs, 
especially those comprising the substrate binding site (TMs 1, 3, 6 and 8), has 
already proved that this structure could be used as a framework for molecular 
modeling and analysis of NSSs active sites [70-72]. The major differences are 
found within the loops and cytoplasmic tails, more specifically the much smaller 
EL2 in LeuTAa and the absence of N- and C-terminal tails, which harbor post- 
translational modifications and protein-protein interaction domains in the 
mammalian counterparts. The divergences observed in these regions highlight 
their importance in the regulation of ion/substrate ratios and transport function, 
and further the non-conserved residues in the binding pocket are thought to be 
important determinants of substrate specificity for each of the NSSs [71].
Pharmacological Aspects of the Dopamine Transporter
The synthesis, storage, release, reuptake, recycling and metabolism of DA 
tightly control the homeostasis of the dopaminergic system. DAT plays a major 
regulatory role by modulating the amount of DA in the synaptic cleft, thereby 
controlling the intensity and duration of the nerve impulse. When the activity of
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the transporter is disturbed, such as in the presence of cocaine and AMPH, the 
levels of DA in the extracellular space are increased. As a consequence, post- 
synaptic neurons become stimulated to supraphysiological levels, resulting in 
euphoria and psychomotor stimulation, and ultimately in behavioral 
reinforcement. This gives rise to what is known as the “dopamine hypothesis of 
reinforcement” (Figure 6) [73].
Inhibitors
Cocaine is a psychostimulant drug with euphorigenic and reinforcing 
properties, which are believed to be critical determinants for its abuse and 
dependence. It is the fifth most widely abused stimulant in western countries and 
possesses characteristics common to other addictive substances, such as 
tolerance to some of its effects and psychological withdrawal syndrome. Cocaine 
is a naturally occurring alkaloid in the leaves of Erythroxylon coca, a plant 
endemic in South America, and has been the topic of extensive scientific 
investigation since the beginning of the 20th century. Its physiological effects 
include local anesthesia and sympathetic as well as psychomotor stimulation, 
which provide this agent with an exceptional potential for abuse [reviewed in 74], 
Today it is classified as a Schedule II drug, meaning that it has high potential for 
abuse, but can be administered by a physician for legitimate medical uses, such 
as local anesthesia for some surgeries [75]. Cocaine has been demonstrated to 
act as an uptake inhibitor of NE, serotonin (5-HT) and DA via binding to their 
cognate transporters, and to have effects on cholinergic, muscarinic and sigma
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Figure 6. The Dopamine Hypothesis of Reinforcement. The normal functioning 
dopaminergic system (left panel) is disturbed by the presence of cocaine (®) 
(right panel), which binds to DAT (purple trapezoids) and inhibits its transport 
activity. As a result, there is an increase in DA concentration at the synaptic cleft 
(blue dots) with stimulation of the pre- and post-synaptic receptors (magenta and 





receptors [reviewed in 74,76]. However, its reinforcing properties have been 
specifically related to its inhibitory actions at DAT (Figure 6).
Other substances that function as DAT uptake inhibitors and join cocaine 
in this group include the therapeutic agents GBR 12909 (originally developed to 
treat cocaine addiction), bupropion (Wellbutrin®, an antidepressant), 
methylphenidate (Ritalin®, therapy for ADHD), and mazindol (Mazindor®, an 
appetite suppressant) (Figure 7).
Substrates
Amphetamines (AMPH and methamphetamine-METH) are also powerful CNS 
psychostimulants. They were first synthesized at the end of the 19th century from 
the alkaloid ephedrine, the active principle from the leaves of Ephedra species. 
The physiological effects of AMPH and METH include euphoria, psychomotor 
stimulation, decrease in appetite, and general sense of well-being. The main 
difference between these substances resides in the fact that, at comparable 
doses, METH reaches the CNS much faster and has longer-lasting effects than 
AMPH, having greater potential for abuse. AMPH (Aderall®) is currently used as 
a standard therapeutic agent for ADHD and narcolepsy, but METH is classified 
as a Schedule II drug due to its high abuse potential [77,78]. In contrast to 
cocaine and because of their chemical resemblance to dopamine (Figure 7), 
amphetamines act as competitive substrates for DAT and become transported 
into the presynaptic neuron. The end result is similar to that of cocaine with 
respect to increased availability of DA at the synapse. In addition, these 
substances cause redistribution of vesicular DA into the cytoplasm, and
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Figure 7. Dopamine Transporter Substrates and Inhibitors. Chemical structures 
of A. the physiological substrate dopamine, and the psychostimulants 
amphetamine and methamphetamine that act as substrates at DAT; B. the 
neurotoxins 6-hydroxydopamine and 1-methyl-4-phenylpyridinium, which are also 
transported by DAT and cause intracellular oxidative damage; C. the uptake 
inhibitors cocaine, GBR 12909 and methylphenidate (Ritalin®) that bind to DAT 






reverse transport of DA by DAT, inducing a tremendous spill of DA into the 
synaptic space [79, reviewed in 64 and 77],
Neurotoxins
DAT has also been demonstrated to be the gateway for several 
neurotoxins that act as substrates and become transported into the cytoplasm 
due to their structural resemblance to DA. 1-methyi-4-phenylpyridinium (MPP+) is 
the oxidation product of the widely characterized neurotoxin 1-methyl-4-phenyl- 
1,2,3,6-tetrahydropyridine (MPTP) (Figure 7). MPP+ enters the neuron through 
DAT and triggers harmful intracellular events that include oxidative stress and 
disruption of mitochondrial respiration, ultimately leading to selective neuronal 
deterioration and Parkinson-like syndrome in mammals [80,81]. The naturally 
occurring toxin 6-hydroxydopamine (6-OHDA) is produced by non-enzymatic 
hydroxylation of DA and is widely used to obtain animal models of PD. Once 
inside the cell it causes oxidative stress via production of reactive oxygen 
species (ROS), leading to cellular, mitochondrial and DNA damage [80,81].
The toxic actions of these substances in dopaminergic neurons and the 
fact that they cause their detrimental effects by entering the cell through DAT 
suggest a potentially important role of this protein in the selective degeneration of 
DA neurons characteristic of PD. Despite the presence of evidence suggesting 
an environmental component in the etiology of idiopathic PD, researchers have 
yet to find a specific toxin in the brains of these patients and the DAT hypothesis 
appears to be one of several factors contributing to the cascade of events that 
leads to the pathogenesis of PD [80].
30
Lessons from DAT Knockout Mice
The role of the dopaminergic system in association with the molecular 
events that lead to drug abuse, and specifically the involvement of DAT in 
maintaining neuronal homeostasis has been strengthened and extended by 
studies in knockout animals. In 1996, Caron and coworkers reported the 
production and analysis of a DAT knockout mouse (DAT7') that exhibits unique 
neurochemical and behavioral characteristics [82]. The biochemistry of the 
nigrostriatal DA system is profoundly altered in these animals, with elevated 
extracellular DA levels, disrupted DA removal, decreased levels of intracellular 
DA and TH, and down-regulation of pre- and post-synaptic DA receptors. In 
these animals, DA persists in the extracellular space at least 100 times longer 
than in the presence of DAT because diffusion is the only remaining mechanism 
for DA clearance. DA knockout mice display highly elevated spontaneous 
locomotion (5-6 times more active), reduced size, cognitive deficiencies, and 
sleep impairment [reviewed in 83, 84]. Injections of high doses of cocaine and 
AMPH in the striatal tissue produced no significant increases in locomotor 
effects. In addition, methylphenidate and MPTP also fail to affect DA-related 
processes in these animals [reviewed in 83]. Interestingly, despite the lack of 
locomotor effects in the presence of cocaine, DAT knockouts do self-administer 
cocaine [85], indicating contribution of a different system in the reward 
mechanism. Identification of sites for cocaine binding and neuronal activation 
implicated the 5-HT system [85], as further supported by the lack of conditioned
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place preference behavior (an indication of reward) in the DAT/SERT double 
knockout mouse [86],
These knockout studies demonstrate the involvement of DAT in processes 
related to modulation of DA concentrations and further substantiate its crucial 
role in maintaining pre- and post-synaptic DA homeostasis. In addition, these 
models demonstrate the complexity of the monoaminergic systems and the 
contribution of various mechanisms in mediating psychostimulant self­
administration and reward.
Substrate and Ligand Binding Sites
The first step in the translocation process involves the selective binding of 
substrates and ions to DAT. Inhibitors also bind to DAT but they are unable to be 
transported across the plasma membrane. A number of distinct structural 
elements present in substrates and inhibitors are involved in the high affinity 
recognition of their binding site on DAT. DA most likely appears in cationic or 
zwitterionic form at physiological pH, where the catechol ring is postulated to be 
necessary for binding, and the amine side chain is thought to mediate the 
conformational switches necessary for transport [87-89], Additionally, the majority 
of the non-DA substrates are phenethylamine analogues that contain a 
protonated amine group, apparently involved in their recognition by the 
transporter [89], In the case of cocaine the tropane ring, the bridged tropane 
nitrogen and the phenyl-ester moiety represent essential elements for normal 
DAT binding [74]. Together the structural features of DA, phenethylamine
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derivatives, and cocaine are potentially recognized by DAT through a variety of 
interactions involving charged, aromatic and polar residues [90].
The DAT interaction domains for substrates and uptake-blockers have 
been extensively studied through a variety of approaches in an attempt to obtain 
insight into the structural implications of the translocation pathway. 
Understanding the relationship between structure and function at DAT is crucial 
in the development of pharmacotherapy directed against drug abuse and DA- 
related syndromes. According to these studies the active sites reside within the 
TM domains, with the loops functioning in a structural/conformational role. 
Traditional binding and uptake experiments suggested that the recognition site 
for DA and inhibitors was indistinguishable or mutually exclusive [91]. However, 
evidence from chimeras and site-directed mutagenesis implicate several distinct 
and shared domains in substrate and blocker binding.
DAT/NET constructs revealed the involvement of TMs 1-3 in both DA and 
blocker interaction, and TMs 5-8 in the recognition of blockers only [92,93], 
Additionally, human/bovine DAT chimeras demonstrated that the concomitant 
presence of TM3 and TMs 6-8 was necessary for high affinity cocaine binding, 
suggesting that several domains participate in the recognition of uptake blockers 
[94,95].
More precise localization of the specific amino acids present in the active 
site within these domains was achieved through site-directed mutagenesis. The 
first DAT amino acid demonstrated to participate in interactions with both DA and 
cocaine was D79, located in the middle of TM1 [96], Interestingly, D79 is one of
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only two negatively charged residues located within DAT TMs and further it is 
conserved within the monoamine NSSs. Replacement of D79 with alanine, 
glycine or glutamate results in profound decreases in DAT affinities for DA and 
the cocaine analogue CFT (2ft-carbomethoxy-3fJ-(4-fluorophenyl)tropane) [96]. 
TM1 additionally contains the residues F76 and W84, which were demonstrated 
to be involved in cocaine binding by site-directed mutagenesis [97,98]. V152 is 
predicted to lie within DAT TM3 and analysis of its replacement to isoleucine 
supports participation in cocaine analogue binding [99], The TMs 6-8 residues 
D313, F320, G323, Y335, D345, and D436 have also been implicated in 
mechanisms involved in transport and inhibitor binding [97,98,100,101].
Although these domains are distant in the primary structure of DAT, their 
involvement in substrate and blocker binding suggests they lie close together in 
the tertiary structure and are part of a common binding pocket in DAT. Additional 
evidence for the three-dimensional juxtaposition of domains was provided by the 
identification of an endogenous extracellular zinc (Zn2+) binding site in DAT. 
Coordination of Zn2+ by residues H193 in EL2, and H375 and E396 in EL4 
requires an ideal distance of 4 A among them, positioning these domains in close 
proximity in the three-dimensional arrangement of the protein [102-104]. 
Engineering artificial Zn2+ binding sites into DAT has been useful to further define 
secondary and tertiary structure at the extracellular side of TMs 7 and 8, and to 




In addition to the use of reversible competitive analogues and the above 
described approaches, the functional domains and the active site in DAT have 
been studied using photoaffinity ligands. Photoaffinity labeling enables direct 
probing of the target protein through a covalent bond, which is photochemically 
introduced between a ligand and its specific receptor. This method requires the 
use of a bioactive ligand analogue with high affinity for the recognition site that 
contains a light-sensitive moiety. The action of ultraviolet (UV) light produces a 
highly reactive species that binds irreversibly to the biological receptor at or near 
the active site [108,109].
A number of structurally diverse photoaffinity probes have been used to 
study DAT, including structural analogues of cocaine, GBR 12909 and 
benztropine. These analogues are composed by their cognate pharmacophore 
core containing the essential structures for reversible binding to DAT, in addition 
to a photoactivatable iodo-azido moiety, where the azido (N3) is the reactive 
group that enables irreversible attachment and the reactive iodine ([125l] serves 
as a tracer (Figure 8). With this technique, the radiolabeled analogues are 
covalently incorporated into DAT and subjected to peptide mapping in order to 
localize the attachment site. For the peptide mapping approach, photolabeled 
DATs are subjected to protease treatment for relatively short periods of time, 
after which large, well-defined fragments are generated. These fragments are 
then analyzed by immunoprecipitation using antibodies directed against specific 
epitopes in DAT, followed by sodium dodecyl sulphate polyacrylamide gel
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Figure 8. DAT Incorporation Domains for Photoaffinity Labels. A. Chemical 
structures of the photolabels analyzed to date. [125I]DEEP and [125l]AD-96 are 
GBR analogues, [125I]RTI 82 is a cocaine analogue, and [125I]GA 2-34 is a 
benztropine analogue. B. Schematic diagram of hDAT indicating the domains of 
ligand incorporation (magenta and blue cylinders), the relative positions of the 
antibody 5 and 16 epitopes (colored bold lines), and the potential trypsin 
cleavage sites (yellow circles).
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electrophoresis (SDS-PAGE), and autoradiography. Two DAT-specific antibodies 
have been widely used for the immunoprecipitation procedures and have 
enabled the identification of distinct iabeled regions within the protein. Antibody 
16 is directed against amino acids 42-59 in the N-terminal tail, and antibody 5 is 
generated against amino acids 225-238, located in EL2 (Figure 8).
Using photoaffinity labeling in combination with peptide mapping, two 
distinct regions in DAT, TMs 1-2 and TMs 4-7, become consistently labeled by 
structurally diverse uptake-blocker analogues. The GBR analogue [125I]DEEP 
and the benztropine analogue [125I]GA 2-34 become incorporated in the TMs 1-2 
region [110-112], and the cocaine analogue [125I]RTI 82 becomes incorporated in 
TMs 4-7 [110,111]. Interestingly, the piperidine analogue [125]AD-96 becomes 
incorporated into both of these regions [113] (Figure 8). This represents 
additional evidence supporting the proximity of these domains in the three- 
dimensional structure of DAT, and implies that uptake-blockers bind to a 
common pocket composed of multiple DAT regions.
Photolabeling, Chemical Cleavage and Site-Directed Mutagenesis
Specific characterization of the exact amino acid to which these 
compounds bind in DAT is limited by the enzymatic cleavage and antibody-based 
approach. This method only allows positive identification of labeled fragments 
that retain the antibody epitopes. Since DAT contains many potential cleavage 
sites within or close to these epitopes, labeled fragments could be generated but 
they would not be immunoprecipitated by the antibody. Recently, our laboratory 
was able to localize the specific [125I]RTI 82 incorporation domain in DAT to TM6
3 8
through the use of chemical cleavage in combination with site-directed 
mutagenesis [114], Proteolysis of [125I]RTI 82 labeled DAT was performed using 
cyanogen bromide (CNBr), which specifically cleaves at the C-terminal side of 
methionine residues. hDAT and rDAT contain only 13 and 15 methionines, 
respectively, scattered throughout the sequence. Additionally, based on the 
antibody identification of TMs 4-7 as the [125I]RTI 82 attachment region, several 
methionines were engineered into the hDAT sequence to create mutants in 
combinations such that the size of the labeled fragments obtained by CNBr 
treatment would be consistent with incorporation at a particular domain within this 
region. This combination strategy allowed the positive identification of a region 
containing residues from EL3, TM6, and IL3 as the [125I]RTI 82 labeled domain. 
This finding was further confirmed by subjecting the labeled fragment obtained by 
CNBr cleavage to a second round of digestion using the enzyme Lys-C. This 
generated a reduced-mass labeled fragment, consistent with TM6 being the 
[125,]RTI 82 incorporation domain. This combination approach thus proved to be 
an effective strategy to delineate the specific domains to which the photolabels 
become incorporated in DAT.
The present studies describe the characterization and localization of the 
binding site for [125I]MFZ 2-24 (A/-[4-(4-azido-3-[125l]iodophenyl)butyi]-2-
carbomethoxy-3ft-(4-clorophenyl)tropane) in DAT using photoaffinity labeling, 
peptide mapping, chemical cleavage and site-directed mutagenesis. [125I]MFZ 2- 
24 is a cocaine analogue whose pharmacophore is identical to that of [125I]RTI 82 
but the phenyl-iodo-azido moiety is placed differentially within the cocaine core
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(Figure 9). Since these compounds share the essential structures for reversible 
cocaine binding, they should bind in the active site with identical orientation, and 
the differential positions of the reactive groups should provide distinctive 
irreversible incorporation patterns within the pocket. This would allow the positive 
identification of the TMs that constitute the binding pocket for cocaine in DAT, 
and would provide an estimation of the proximity of these domains within the 
pocket. In addition, a third cocaine analogue in these series of compounds, 
[125l]JHC 2-48 (3-(4’-azido-3’-iodo-phenyl)-8-methyl-8-aza-bicyclo-[3.2.1]octane- 
2-carboxylic acid methyl ester) was initially analyzed and characterized through 
peptide mapping in comparison to [125I]MFZ 2-24 and [125I]RTI 82. [125I]JHC 2-48 
contains the reactive group appended to the phenyl ring in the pharmacophore 
(Figure 9), and the localization of its incorporation site will provide further 
evidence for the identity of the domains that compose the binding pocket for 
cocaine in DAT.
These studies additionally describe the binding characteristics and the 
irreversible incorporation into DAT of the GBR analogue [125i]D-147 (1-{2-[(4- 
Azido-3-iodo-phenyl)-phenyl~methoxy]-ethyl}-4-phenethyl-piperazine oxalate) 
using photoaffinity labeling and peptide mapping. [125I]D-147 is identical in 
structure to the previously characterized GBR-like compound [125]DEEP, with the 
iodo-azido reactive group attached in a different position with respect to the 
piperazine pharmacophore (Figure 9). The comparison of the irreversible 
attachment sites for these related compounds will provide essential information
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Figure 9. Chemical Structures of Photoaffinity Labels. A. Cocaine and cocaine- 
based photolabels are shown. [125I]RTI 82 attachment to DAT has been 
previously characterized [110,111,114]. Incorporation profiles of [125I]MFZ 2-24 
and [125I]JHC 2-48 into DAT are described in these studies. B. GBR 12909 and 
GBR-based photolabels are depicted. Incorporation of [125I]DEEP into DAT has 
b .e.i previously described [110,111]. [125I]D-147 attachment to DAT is 





about the components of the binding site for GBR-like compounds and will further 
our understanding of how the TMs in DAT are three-dimensionally oriented.
Previous studies using both GBR and cocaine classes of compounds have 
suggested that they share a common binding pocket composed of multiple TM 
domains. The present studies represent the first time that photoaffinity labels 
carrying identical pharmacophores will be used to directly compare their 
incorporation patterns. The obtained results will allow for correlation of the 
information obtained from identifying the attachment sites for both classes of 




MATERIALS AND METHODS 
Materials 
Animals
Male Sprague-Dawley rats (175-300 g) were obtained from Charles River 
Laboratories (Wilmington, MA) and were housed and treated in accordance with 
regulations approved by +he University of North Dakota Institutional Animal Care 
and Use Committee and the National Institutes of Health.
Reagents
[125I]MFZ 2-24, [125I]RTI 82, [125I]D-147, and [125I]JHC 2-48 were 
synthesized by Dr. Amy Newman (NIDA), Dr. Mu-Fa Zou (NIDA), Dr. Joo Whan 
Cha (NIDA) and Dr. Aloke Dutta (Wayne State University), and radioiodinated by 
Dr. John Lever (University of Missouri) as previously described [115-118], 
Trypsin, trypsin inhibitor, dopamine, (-)-cocaine, GBR 12909, nomifensine, 
mazindol, desipramine, imipramine, citalopram, nisoxetine, fluoxetine and CNBr 
were from Sigma-Aldrich (St Louis, MO). (+)-Cocaine was the generous gift of Dr. 
Maarten E.A. Reith (New York University School of Medicine, New York, NY). 
[3H]2li-carbomethoxy-3ft-(4-fluorophenyl)tropane (CFT) was from Perkin Elmer 
Life and Analytical Sciences (Boston, MA). Protein A Sepharose CL4B beads, 
[3H]dopamine, and high- and low-range Rainbow Molecular Weight Markers
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Markers were from Amersham Biosciences/GE Healthcare (Piscataway, NJ). 
Electrophoresis reagents were from Bio-Rad (Hercules, CA). Human Embryonic 
Kidney (HEK) 293 cells were from ATCC (Manassas, VA), HEK 293 cells 
expressing hSERT were kindly provided by Dr. Randy Balely (Vanderbilt 
University, Nashville, TN), and Lewis Lung Carcinoma Porcine Kidney (LLCPKi) 
cells expressing rDAT were the generous gift of Dr. Gary Rudnick (Yale 
University, New Haven, CT). Complete Mini protease inhibitor and FuGENE 6 
transfection reagent were from Roche Applied Sciences (Indianapolis, IN). Cell 
culture reagents were from Mediatech (Herndon, VA); the QuikChange 
Mutagenesis kit was from Stratagene (La Jolla, CA). Synthetic oligonucleotide 
primers were purchased from Genscript Corporation (Piscataway, NJ), or MWG 
Biotech Inc (High Point, NC). All other chemicals and reagents were from Sigma- 
Aldrich (St Louis, MO) or Fisher Scientific (Pittsburgh, PA).
Equipment
Centrifuges
A Beckman Avanti J-25 centrifuge with a JA 25.50 or a JA 16.250 rotor 
was used to prepare rat striatal membranes and for purification of plasmids. 
Beckman Microfuge R and Microfuge 18 centrifuges were used for general 
microcentrifugation under refrigerated and non-refrigerated conditions, 
respectively. A Beckman J6-MI swinging bucket centrifuge with a JS 5.2 rotor 
was used for Protein A Sepharose beads preparation and cell pelleting.
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Electrophoresis, electroelution and dialysis
Sodium dodecyl sulphate (SDS) poly-acrylamide gel electrophoresis 
(PAGE) was performed using the Gibco/BRL Life Technologies Model V16 gel 
system or the Bio-Rad Mini-Protean III electrophoresis device. Transfer of 
electrophoresed proteins was performed using a Bio-Rad Mini trans blot 
electrophoresis transfer cell. Electrical voltage and current for both processes 
was monitored by the Gibco/BRL Life Technologies 250 EX power supply. Gels 
were dried using a Bit-Rad Model 583 gel dryer.
Electroelution of proteins was performed using the Bio-Rad Model 422 
Electroeluter with 3,500 MW cutoff membrane caps. Electroeluted proteins were 
dialyzed using Pierce Slide-A-Lyzer® cassettes with 10,000 MW cutoff. 
Spectroscopy
A Molecular Devices SpectraMax 190 plate reader was used to quantify 
Bicinchoninic acid (BCA) protein assays and a Beckman DU640 
spectrophotometer was used to quantify plasmid DNA. a  rackard 1900CA or a 
Beckman LS6500 liquid scintillation counter was used to analyze incorporation of 
radioactivity during binding and uptake experiments.
Cell culture, molecular biology and miscellaneous equipment
Mammalian cells were grown and maintained in a Nuaire 2700-30 water- 
jacketed C 02 incubator, and sterilely managed in a Nuaire Class II type A/B3 
laminar flow hood. An Eppendorf Mastercycier Personal thermocycler was 
utilized to perform procedures involving Polymerase Chain Reaction (PCR). A 
Polytron PT2100 homogenizer was used to homogenize rat striatum for
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membrane preparations. A Thermo Savant SpeedVac® evaporator was used to 
dry dialyzed and CNBr digested samples. A Fotodyne ultraviolet (UV) lamp 




Male Sprague-Dawley rats (175-300 g) were decapitated and the striatal 
tissue was immediately removed and weighed, after which it was placed in ice- 
cold sucrose-phosphate (SP) buffer (10 mM sodium phosphate piuc 0.32 M 
sucrose, pH 7.4) and homogenized with a Polytron Homogenizer in setting 11 for 
12-15 sec. Homogenate tissue was subjected to centrifugation at 20,000 xg for 
12 min at 4 °C, and the resulting membranes were washed twice by 
centrifugation in ice-cold SP buffer and resuspended to 20 mg/mL original wet 
weight (o.w.w.). [125I]MFZ 2-24, [125I]RTI 82, [125I]D-147 and [125I]JHC 2-48 
reaction mixtures were prepared in SP buffer, added to the membranes at a final 
concentration of 5 nM, and incubated for 60 min at 0 °C to allow reversible 
binding. For pharmacological competition studies, saturating concentrations (1- 
10 pM) of non-radioactive transporter inhibitors and substrates were added to the 
binding mixture. Irreversible attachment of the photoaffinity ligands to DAT was 
carried out by directly irradiating the sample with UV light (254 nm) for 45 sec at 
a distance of 1 cm. The resulting photolabeled membranes were washed three 
times by centrifugation with SP buffer and subsequently solubilized at 20 mg/mL 
o.w.w. in SDS-PAGE sample buffer (60 mM Tris-HCI pH 6.8, 100 mM
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dithiothreitol, 10% glycerol, 2% SDS and 0.001% bromophenol blue) or SP buffer 
for in situ proteolysis or 0.5% SDS sample buffer (60 mM Tris-HCI pH 6.8, 100 
mM dithiothreitol, 10% glycerol, and 0.5% SDS) for immunoprecipitation.
hDAT/rDAT/hSERTExpressing Cells
Wild type hSERT, and wild type and mutant hDAT and rDAT cells were 
plated onto 6-well plates and grown to 90-95% confluence. Growth medium was 
removed and the cells were incubated with 5 nM radioligand reaction mixtures 
prepared in Krebs Ringers HEPES (KRH) buffer (25 mM HEPES, 125 mM NaCI, 
4.8 mM KCI, 1.2 mM KH2P04, 1.3 mM CaCI2, 1.2 mM MgS04, 5.6 mM glucose, 
pH 7.4) for 60 min at 22 °C to allow reversible binding. For cocaine displacement 
studies, a 50 pM solution of cocaine was prepared in KRH buffer and added to 
the binding mixture. The ligands were covalently incorporated into DAT by direct 
irradiation with UV (254 nm) light for 45 sec at a distance of 1 cm. Photolabeled 
cells were washed twice with 1 mL/well KRH and solubilized with 500 pL/well 
Triton buffer (1% Triton X-100, 25 mM Tris base, 150 mM NaCI, 1mM EDTA) 
supplemented with Complete Mini protease inhibitor at 0 °C for 30-45 minutes. 
Lysates were centrifuged at 20,000 xg for 15 min at 4 °C and supernatants were 
collected and used for further analysis.
Gel Purification, Electroelution and Dialysis 
Solubilized radiolabeled DATs from rat striatal membranes or cells were 
subjected to purification by SDS-PAGE on 10% tris-glycine gel systems. Gels 
were dried and exposed to autoradiographic film for 6-16 h. The -80 kDa labeled 
bands that correspond to DAT were excised, removed and rehydrated in 1X
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SDS-PAGE running buffer (25 mM Tris, 192 mM Glycine and 0.1% SDS). 
Rehydrated gel pieces were subjected to electroelution at 10 mA/tube for 5.5 h, 
and electroeluates were dialyzed against 1 L of MilliQ purified water for 20-24 h 
followed by evaporation to dryness in a SpeedVac® concentrator.
In situ Trypsin Proteolysis
Photolabeled rat striatal membrane suspensions prepared at 20 mg/mL in 
SP buffer were subjected to treatment for 10 min at 22 °C with equal volumes of 
trypsin prepared in SP buffer at final concentrations of 10-200 pg/mL. At the end 
of the incubation one volume of 1 mg/mL trypsin inhibitor was added to halt the 
digestion process, followed by centrifugation at 20,000 xg for 12 min at 4 °C. The 
resulting pellets were solubilized with 0.5% SDS sample buffer.
In solution Cyanogen Bromide Digestion 
Dried electroeluted and dialyzed extracts were incubated for 24 h at 22 °C 
in the dark with 0.1 mL of 1M CNBr prepared in a 70% formic acid solution or 
with 70% formic acid solution alone. Quenching of the reaction was achieved by 
addition of 0.9 mL MilliQ water followed by evaporation to dryness in a 
SpeedVac® concentrator. The samples were subjected to three additional rounds 
of suspension in water and drying to remove residual volatile acidity. The final 
dried samples were resuspended in either sample buffer for analysis by 
electrophoresis and autoradiography, or immunoprecipitation buffer (50 mM Tris- 
HCI, 0.1% Triton X-100, pH 8.0) (IPB) for analysis by immunoprecipitation, 
electrophoresis and autoradiography.
4 9
Immunoprecipitation, Electrophoresis and Autoradiography 
Solubilized radiolabeled DATs or DAT fragments were subjected to 
epitope-specific immunoprecipitation as described previously [112,113] with 
minor modifications, using antiserum 16 generated against amino acids 42-59, or 
antiserum 5 generated against amino acids 225-238. Briefly, protein A sepharose 
beads were hydrated and washed three times with IPB, and resuspended in IPB 
plus 0.05% sodium azide (NaN3). Polyclonal antibody (20 pg) was bound to the 
hydrated beads for 3-6 h at 4 °C with rotation followed by three washes with IPB. 
Alternatively, protein A sepharose beads were hydrated in triethanolamine (TEA) 
buffer (0.2 M TEA, pH 8.0), incubated with polyclonal antibody for 45 min at 22 
°C and washed twice with TEA buffer; the antibody was cross-linked to the beads 
by incubation with DMP (Dimethyl pimelimidate) for 45 min at 22 °C, after which 
the beads were washed twice with 100 mM Tris pH 8.0, rinsed with IPB and 
resuspended in IPB plus 0.05% NaN3. Samples were incubated with either bead 
slurry for 3 h at 4 °C with rotation, suDsequently washed four times with IPB and 
eluted with sample buffer. For peptide competition experiments, diluted 
antibodies were preabsorbed with 50 pg/mL of peptide 16 or peptide 5 before 
sample addition. Total and immunoprecipitated samples were electrophoresed 
on SDS-PAGE 9-16%, 16%, 18% or 20% gels at 6-8 mA for 16 h, followed by 
autoradiography using Hyperfilm™ MP or Kodak BioMax MS film for 1 to 4 days 




Solubilized rat striatal membranes or cell lysates were subjected to 
separation by SDS-PAGE on 10%, 4-20%, or 10-20% tris-glycine polyacrylamide 
gels at 125 V for 2 h. Separated proteins were transferred to 0.45 or 0.2 pm 
polyvinylidene fluoride (PVDF) membranes at 100 V for 2 h in transfer buffer (10 
mM Tris, 100 mM glycine, 0.01% SDS and 10% methanol) at 4 °C. 
Subsequently, PVDF membranes were blocked for >3 h with 3% bovine serum 
albumin (BSA) in phosphate buffer saline (PBS) (BSA/PBS buffer) at 4 °C. DAT 
protein was detected with the hDAT specific rat monoclonal antibody MAB 369 
(Chemicon/Millipore, Temecula, CA) generated against DAT N-terminal tail. A 
1:1000 dilution of MAB 369 in BSA/PBS buffer was incubated with the blocked 
PVDF membranes for 1 h at 22 °C. Removal of unbound antibodies was 
achieved by washing the membranes four times with PBS/Tween buffer (PBS 
plus 0.1% Tween-20). Detection of the primary antibody was achieved by 
incubating the membranes with a 1:20,000 dilution of alkaline-phosphatase 
linked anti-rat IgG (Sigma-Aldrich) for 1 h at 22 °C, followed by removal of 
unbound antibodies by washing the membrane four times with PBS/Tween 
buffer. The membranes were developed using the alkaline phosphatase 
substrates lmmun-Star™AP (Bio-Rad) for 5 min or 5-bromo-4-chloro-3-indolyl 
phosphate/nitro blue (BCIP/NBT) (Sigma-Aldrich) for 5-10 min. Immun-Star™ 
treated membranes were visualized with a Boehringer-Manheim Lumi Imager 
and quantified using LumiAnalyst 3.0 software. BCIP/NBT treated membranes
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were dried, scanned on an Epson 1200 scanner as tagged image format files 
(TIFF) images, and quantified using LumiAnalyst 3.0 software.
QuikChange® Site-Directed Mutagenesis 
An N-terminal wild-type (WT) 6xHis-human (h) DAT in a pcDNA 3.1/His®B 
vector was used as the starting template for mutagenesis. Selected residues 
were mutated using the QuikChange® method in order to generate or eliminate 
CNBr cleavage points. The oligonucleotide primers utilized for codon substitution 
were designed through the PrimerX website (http://bioinformatics.org/primerx) 
and synthesized by GenScript Corporation or MWG Biotech (Appendix B). The 
reaction mixture was prepared in 200 pL PCR tubes following the parameters in 
Table 1. The reaction was initiated by the addition of 1 pL of PfuTurbo DNA 
Polymerase (2.5 U/pL) and cycled according to the cycling parameters described 
in Table 2.
Table 1. QuikChange® Reaction Mixture
Volume (pL) Reagent
5 10X Reaction buffer (100 mM KCI, 100 mM(NH4)2S04, 200 mM Tris- 
HCI pH 8.8, 20 mM MgS04, 1% Triton® X-100,1 mg/mL nuclease-free 
BSA)
20 Template DNA (5 ng/pL)
1.25 Oligonucleotide primer #1 (125 ng)
1.25 Oligonucleotide primer #2 (125 ng)
1 dNTP mix
21.5 Double distilled DNAse free H20
50 Final Volume
5 2
Table 2. QuikChange® Thermal Cycling Parameters
Segm ent Cycles Tem perature Tim e
1 1 95 °C 30 seconds
2 16 95 °C 30 seconds
55 °C 1 minute
O000CD 8 minutes
Following the thermal cycling process, 1 pL of the Dpnl restriction enzyme 
(10 U/pL) was added to the reaction mixture and incubated at 37 °C for 1 h to 
degrade the template supercoilea double-stranded DNA. The resulting 6xHis- 
hDAT pcDNA 3.1/His®B plasmid (Figure 10) was transformed into either 
NovaBlue competent cells (Novagen) or XL1-Blue supercompetent cells 
(Stratagene) according to the manufacturers’ guidelines.
Plasmid Amplification and Isolation
Transformed cells were plated on 1.5% agar plates containing 100 pg/mL 
carbenicillin, followed by incubation at 37 °C for >16 h to obtain colonies. Colony 
development was achieved by collection of one colony of cells from the selective 
agar followed by growth in Glucose M9Y medium complemented with 100 pg/mL 
carbenicillin. The plasmid DNA was isolated using the PureYield® Plasmid 
Midiprep System (Promega), visualized through separation by electrophoresis on 
c 1% agarose gel (0.5 pg/mL ethidium bromide) with the GrabIT Annotating 
Grabber 2.04.6 (UVP Inc, Upland, CA), and quantified using the BioRad 
Molecular Analyst™ software version 1.0 (1992-1996). Additionally, the DNA 
concentration of the sample was measured by spectrophotometry at 260 nm 
using the following formula: [DNA (pg/mL)] = A26o (50) (dilution factor). The final
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Figure 10. Schematic Diagram of the 6xHis-hDAT pcDNA 3.1/His B Plasmid. 
The major regions of this fusion vector are depicted here. Shown are the CMV 
immediate-eariy promoter (yellow), the oxriistidine sequence, the hDAT 
sequence (blue), the SV40 early promoter (green), the Neomycin resistance 
gene (purple), the Ampicillin resistance gene (magenta), and the polyadenylation 
signal (black and white). Additionally, the restriction sites used to insert the hDAT 











concentration of the plasmid DNA was obtained as an average of the two 
methods used for quantification. To verify the presence of the desired mutation(s) 
oligonucleotide primers were generated (Appendix C), the DAT insert was 
sequenced by Northwoods DNA (Solway, MN) or Alpha Biolabs (Sunnyvale, CA) 
and analyzed using Vector NTI software (Invitrogen).
Transfection of HEK 293 Cells
Stable transfection of Human Embryonic Kidney (HEK) 293 cells was 
achieved by growth of parental HEK 293 cells to 40-60% confluency in T25 flasks 
and transfection through the FuGENE 6 reagent in a 3:1 FuGENE 6 to DNA ratio 
mixture (Table 3). The FuGENE 6/DNA mixture was prepared in serum-free 
complete medium (Dulbecco’s modified Eagle’s medium-DMEM, 2 mM L- 
glutamine), gently mixed and incubated at 22 °C for 15-30 min.
Table 3. FuGENE 6 Transfection Reaction Volumes
Mutants
Reagents M116A M111L/M116L L80M/ I67M/
(HL) M111L/M116L M111L/M116L
FuGENE 6 12 12 12 12
DNA (4 pg) 21 14 11 19
(Concentration) (193 ng/pL) (300 ng/pL) (356 ng/pL) (212 ng/pL)
Media 217 234 227 219
Final Volume 250 250 250 250
Following incubation, the transfection reaction mixture was added in a 
drop-wise manner to the cell medium in the T-25 flask containing the parent cells 
and placed in the incubator at 37 °C until 90-95% confluency is reached. For
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selection of effectively transfected cells, the original medium was removed, the 
cells were split 1:2, and selection medium was added (DMEM, 10% fetal bovine 
serum-FBS, 2 mM L-glutamine, 100 U/mL penicillin, 100 pg/mL streptomycin, 
and 600 pg/mL G418). Cells were kept under selection conditions for 2-3 days, 
dead cells were removed, flasks were rinsed with Hanks Balanced Salt Solution 
(HBSS), and selection medium was added. Cells were grown in selection 
medium for ~2 weeks, after which growth medium (DMEM, 10% FBS, 2 mM L- 
glutamine, 100 U/mL penicillin, 100 pg/mL streptomycin, and 250 pg/mL G418) 
was added.
Expression of mutant DATs was verified through immunoblot analysis of 
cell lysates with MAB 369 antibody. Lysates were obtained by solubilizing cells in 
Triton buffer for 30-45 min at 4 °C, and immunoblotted as described above. The 
protein concentration of the lysates was measured by spectrophotometry using 
the BCA method.
Cell Culture and Cell Freezing
Parental HEK 293 cells were grown and maintained in serum-free 
complete medium. 6xHis-hDAT HEK 293 cells were selected, grown and 
maintained in complete medium with either 250 or 600 pg/mL G418. Growth and 
maintenance was performed in T-75 flasks at 37 °C in an incubator gassed with 
5% C 02/95% 0 2.
Once DAT expression was verified by immunoblotting with stably 
transfected cells, stock aliquots were prepared for freezing. Cells were cultured in 
T-75 flasks until 95-100% confluency was achieved. Once confluent, cells were
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collected, pelleted, resuspended in 2-3 mL of freeze medium (10% Dimethyl 
Sulfoxide-DMSO), and aliquoted in properly labeled cryovials. Aliquots of cells 
were gently frozen for 24 h in a Nalgene Cryo 1 °C container, and subsequently 
stored in liquid nitrogen.
Functional Assays
Whole Cell [3H]CFT Binding and [3H]DA Uptake 
HEK 293 cells expressing WT and mutant 6xHis-hDAT were grown in 24- 
well plates until 75-80% confluency was reached, and washed twice with ice-cold 
KRH buffer. For binding assays cells were incubated in quadruplicates with 5 nM 
[3H]CFT in KRH for 2 h at 0 °C, subsequently rinsed twice with KRH, and 
solubilized in 1% Triton X-100. For uptake assays, cells were assayed in 
triplicate for DA transport using a 3 pM DA mixture containing 10 nM [3H]DA in 
KRH, and with 30 pM (-)-cocaine to determine non-specific uptake. Assays were 
carried out for 9 min at 37 °C and stopped by rinsing cells with ice-cold KRH 
followed by solubilization in 1% Triton X-100. Following solubilization, radioactive 
binding and uptake lysates were added to 3 mL of scintillation fluid EcoScint A 
followed by analysis by liquid scintillation counting at 52% efficiency. In order to 
obtain the IC50 values for cocaine inhibition of [3H]CFT binding and [3H]DA 
uptake, assays were performed in the presence of 10'11 -  10^ M (-)-cocaine.
Rat Striatal Membrane [3H]CFT Binding Competition Assay 
In order to determine the binding affinity of the novel ligand D-147 for 
DAT, a [3H]CFT binding competition assay was performed in rat striatal 
membrane preparations. Rat striatal tissue was homogenized in SP buffer, and
5 8
homogenates ce.itrifuged. The resulting membranes were resuspended at 10 
mg/mL o.w.w. in the same buffer. To inititate the binding competition assay, 
triplicate samples of membranes were added to tubes containing 10'10-10'r' M 
concentrations of D-147, and 1 nM [3H]CFT prepared in SP buffer, followed by 
incubation on ice for 2 h. Membranes were then collected and washed three 
times with 5 mL of SP buffer using a Brandel tissue harvester over Whatman 
GF/B glass fiber filters soaked for 1 h in 0.1% BSA/0.05% Polyethylemine (PEE) 
in PBS. Bound radioactivity was quantified by liquid scintillation counting at 52% 
efficiency.
Statistical Calculations and Graphs
The determination of the cocaine IC50 for inhibition of [3H]DA uptake or 
[3H]CFT binding to DAT in WT and mutant hDAT HEK 293 cells, and the 
determination of the D-147 IC50 for binding to DAT in rat striatal tissue were 
performed using non linear regression analysis with Prism 3.0 software 
(Graphpad Software, San Diego, CA). Values were statistically analyzed using 
Analysis of Variance (ANOVA) with Tukey’s Multiple Comparison Test.
Energy Minimization Calculations
Intramolecular distances and energy minimization calculations were 
carried out by Dr. Amy Newman (NIDA-IRP). The intramolecular distances in 
[125I]MFZ 2-24 were obtained using the molecular modeling program SYBYL 6.7 
(Tripos Inc.) with the CFT crystal structure as a template. Energy minimizations 
were performed by conjugate gradient method until a convergence gradient of 




Pharmacology of [125I]MFZ 2-24 incorporation into DAT 
The photoaffinity label [125I]MFZ 2-24 is a cocaine analogue whose 
structure contains tropane and phenyl rings, known essential elements for 
cocaine binding to DAT. [12ol]MFZ 2-24 is structurally identical to the previously 
characterized [125I]RTI 82 [114], except for the position of the pheuyl-iodoazido 
reactive group with respect to the cocaine pharmacophore (Figure 11). Synthesis 
and radioiodination of MFZ 2-24 have been previously described and its IC50 
value for displacement of [3H]CFT in rat striatum was shown to be 33.0 ± 4.7 nM 
[115,116], indicating high affinity for DAT.
Incorporation of [125I]MFZ 2-24 into rat striatal DATs was evaluated in the 
presence of a number of uptake blockers and the physiological substrate DA, in 
order to determine its pharmacological specificity for binding to DAT. Labeling 
was prevented when binding was carried out in the presence of DA or the DA 
uptake inhibitors (-)-cocaine, mazindol, GBR 12909 and nomifensine, but was not 
modified by the inactive enantiomer (+)-cocaine, the NET blocker desipramine or 
the SERT blocker imipramine (Figure 12). These results demonstrate that 
[125I]MFZ 2-24 irreversibly attaches to DAT and that the compounds used in 
these studies act as competitive inhibitors by preventing the reversible
6 0
Figure 11. Chemical Structure of Cocaine-Based Photoaffinity Labels. Cocaine 
and the analogues used in these studies are shown. The phenyl-iodoazido 
moiety that allows the covalent incorporation into the protein is attached to the 
tropane ring C2 carbon in [125I]RTI 82, to the tropane bridge nitrogen in [125I]MFZ 





Figure 12. [125I]MFZ 2-24 Photoaffinity Labeling Displays DAT Pharmacological 
Specificity. Rat striatal membranes were photolabeled with [125I]MFZ 2-24 in the 
presence of the indicated compounds [10 pM final concentrations, except 
imipramine (1 pM) and dopamine (100 pM)]. After labeling, samples were 




incorporation of the ligand. This evidence supports the assumption that the 
irreversible incorporation site is located in or near a DAT domain of significant 
pharmacological importance.
Peptide Mapping of the DAT [125I]MFZ 2-24 Incorporation Site by Trypsin
Proteolysis
Trypsin is a serine protease that cleaves proteins at the carboxyl side of 
lysine and arginine residues. The DAT sequence contains several potential 
trypsin sites (Figure 13), but for our peptide mapping studies using membrane 
preparations, only those located in the interhelical loops are accessible for 
enzymatic cleavage. In addition, the presence of both the antibody epitope and 
the attached radioactive label is essential for a labeled fragment to be detected 
by this approach. Tryptic maps of [125I]RTI 82 and [125I]DEEP labeled rat striatal 
membranes showed cleavage at the EL2 residue R218 with subsequent 
generation of two distinctive fragments that originate N- and C-terminal to this 
amino acid. Visualization of a glycosylated 45 kDa [125I]DEEP fragment that 
immunoprecipitates with antibody 16 (against residues 42-59), and a non- 
glycosylated 32 kDa [125I]RTI 82 fragment that is precipitated by antibody 5 
(against residues 225-238) (Figure 13) demonstrates the differential 
incorporation of these ligands into discrete domains in DAT [111], This strategy 
was also utilized to delineate the attachment sites for a variety of structurally 
diverse compounds, which became incorporated into one or both of these 
domains (Figure 8), supporting the hypothesis that TMs 1-2 and TMs 4-7 
contribute at least in part to form a common binding pocket for various classes of 
inhibitors [reviewed in 119].
6 5
Figure 13. Potential Trypsin Cleavage Sites and Antibody Epitopes in rDAT. 
Schematic diagram of rDAT showing the arginine (R) and lysine (K) residues as 
the potential trypsin proteolysis sites (yellow). The N-terminal antibody 16 is 




In order to delineate the [125I]MFZ 2-24 irreversible incorporation profile on 
DAT, a tryptic peptide map was performed in parallel with [125I]RTI 82 for direct 
comparison of their incorporation sites. Rat striatal membranes were photoaffinity 
labeled with [125!]MFZ 2 24 and [125I]RTI 82, and subjected to in situ trypsin 
proteolysis followed by immunoprecipitation with N-terminal antibody 16 and EL2 
antibody 5, electrophoresis on a 9-16% gel and autoradiography (Figure 14). 
Cleavage of [125I]MFZ 2-24 labeled DATs generated a prominent 45 kDa 
fragment that precipitates with antibody 16 and a very faint 32 kDa fragment that 
precipitates with antibody 5. These results indicate that incorporation of [125I]MFZ 
2-24 occurs N-terminal to R218, in a DAT domain containing TMs 1-3. In 
contrast, proteolysis of [125I]RTI 82 labeled DATs produced the previously 
characterized 32 kDa fragment that is precipitated by antibody 5, and no 
detectable antibody 16 precipitable fragments (Figure 14).
[125I]MFZ 2-24 labeled rat striatal membranes were treated with increasing 
concentrations of trypsin to more precisely localize the incorporation of the ligand 
into DAT. In addition to the 45 kDa fragment, a 16 kDa fragment that 
immunoprecipitated with antibody 16 was observed at high trypsin 
concentrations, consistent with cleavage at IL1 (Figure 15A). To validate the DAT 
origin of these fragments, photoaffinity labeling was performed in the presence of 
10 pM (-)-cocaine, followed by tryptic proteolysis and immunoprecipitation with 
antibody 16 (Figure 15A). [125I]MFZ 2-24 covalent labeling of the intact DAT, and 
the 45 kDa and 16 kDa fragments (lanes 1, 3, 5 and 7) was completely displaced
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Figure 14. [125I]MFZ 2-24 and [125!]RTI 82 Attach to Distinct Domains in DAT. 
Upper panel: Rat striatal membranes labeled with either [125I]MFZ 2-24 or 
[125I]RTI 82 were treated with or without 50 pg/mL trypsin and 
immunoprecipitated with antiserum 16 or 5, as indicated. Lower panel: Schematic 
diagram of rDAT showing predicted structure and membrane topology. 
Transmembrane (TM) domains are shown as cylinders, the trypsin cleavage site 
on EL2 (R218) is shown as a yellow circle, and antibody epitopes are indicated 
by colored bold lines with numbers. Arrows indicate relationship of 
autoradiograph fragments to domains in schematic DAT. Cleavage at R218 
generated an N-terminal 45 kDa fragment labeled with [125I]MFZ 2-24 that 
originated from TMs 1-3 (magenta), and a C-terminal 32 kDa fragment labeled 












Figure 15. The Cocaine Analogue [125I]MFZ 2-24 Attaches to TMs 1-2 Domain in 
DAT. A. Rat striatal membranes were labeled with [125I]MFZ 2-24 in the presence 
(lanes 2, 4, 6, 8) or absence (lanes 1, 3, 5, 7) of 10 pM (-)-cocaine, treated with 
(lanes 3-8) or without (lanes 1-2) increasing concentrations of trypsin and 
subjected to immunoprecipitation with antiserum 16, followed by electrophoresis 
and autoradiography. Full-length DAT protein migrates at ~80 kDa (arrow a), and 
together with the 45- and 16-kDa N-terminal fragments (arrows b and c), they 
display cocaine displacement of labeling. B. [125I]MFZ 2-24 labeled rat striatal 
membranes were subjected to trypsin (100 pg/mL) proteolysis and 
immunoprecipitation with antibody 16 (lane 1), antibody 16 preabsorbed with 
peptide 16 (lane 2) and antibody 16 preabsorbed with peptide 5 { ane 3), 
demonstrating the immunological specificity of the precipitation of the 45- and 16- 
kDa N-terminal fragments. C. Schematic diagram of rDAT highlighting the 
incorporation domain of [125I]MFZ 2-24 (magenta). The trypsin sites that originate 
the labeled fragments, R123, K132 and R218, are shown as yellow circles and a 
colored bold line indicates antibody 16.
71
A. B.




by cocaine (lanes 2, 4, 6 and 8), demonstrating that the origin of the fragments 
resides within the cocaine binding site in DAT.
Additionally, the immunological specificity of the [125I]MFZ 2-24 labeled 
fragments was verified by preabsorbing antibody 16 with the immunizing peptide 
or the non-immunogenic peptide 5 before subjecting the samples to 
immunoprecipitation (Figure 15B). Trypsin treated labeled rat striatal membranes 
were immunoprecipitated with antibody 16 alone (lane 1), antibody 16 
preabsorbed with peptide 16 (lane 2), and antibody 16 preabsorbed with peptide 
5 (lane 3). Immunoprecipitation of the 45- and 16-kDa fragments with serum 16 
(lane 1) was prevented by the presence of the antigenic peptide (lane 2) but not 
affected by the unrelated peptide 5 (lane 3).
These results indicate that the [125I]MFZ 2-24 labeled 45 kDa fragment 
obtained by trypsin proteolysis and immunoprecipitation originates from rDAT N- 
terminal to the EL2 residue R218 and includes TMs 1-3. More precise 
localization by tryptic treatment generates an additional 16 kDa fragment, 
consistent with cleavage at rDAT R123 or K __ und containing TMs 1-2 (Figure 
15C). There ic. i possibility of labeled fragments smaller than 16 kDa being 
produced by the tryptic treatment, but the proteolytic loss of the antibody epitope 
did not allow their detection by immunoprecipitation. In contrast to the [125I]RTI 82 
irreversible attachment to TMs 4-7, [125I]MFZ 2-24 becomes incorporated into the 
N-terminal TMs 1-2 region in DAT, indicating that differential placement of the 
phenyl-iodoazido arm in the cocaine pharmacophore results in distinct
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incorporation patterns. This represents the first evidence for differential 
incorporation of photoaffinity labels carrying identical pharmacophore. In addition, 
these findings strongly support the hypothesis of three-dimensional proximity 
between the regions encompassing TMs 1-2 and TMs 4-7 in the tertiary structure 
of DAT, and directly implicate these domains in binding of the psychostimulant 
cocaine.
Peptide Mapping of the DAT [125I]MFZ 2-24 Attachment Site by CNBr cleavage
In contrast to enzymatic proteolysis, chemical cleavage of proteins is 
directed to less abundant residues, and consequently results in fewer and larger 
fragments. One of the most commonly used agents for chemical proteolysis is 
cyanogen bromide (CNBr), which cleaves at the C-terminal side of unoxidized 
methionine residues. This digestion occurs with high specificity, few side 
reactions, and average yields of 90-100% [120,121], The rat and human isoforms 
of DAT contain a relatively low number of methionine residues, making them an 
ideal target for the use of this method. The 13 methionines present in hDAT are 
located at positions 1 and 11 within the N-terminal tail; 106, 111, and 116 in TM2; 
272 in TM5; 371 in EL4; 414, 424, and 427 in TM8; 511 in IL5; and 569 and 571 
in TM 12 (Figure 16, black circles). rDAT contains 2 additional methionines at 
positions 173 in EL2 and 290 in EL3 (Figure 16, grey circles).
Within the TMs 1-2 domain in hDAT and rDAT there are five methionines 
that represent potential CNBr cleavage sites. In order to characterize the CNBr 
cleavage profile of [125I]MFZ 2-24-labeled DATs, HEK 293 cells expressing a 6x- 
Histidine tagged hDAT and LLCPKi cells expressing rDAT were utilized. This
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Figure 16. Methionine Residues in DAT. Schematic diagram of hDAT showing 
the TM domains (grey cylinders), the N-glycosylation sites in EL2 (branched 
structures), the position of epitope 16 (highlighted in magenta), the 13 
endogenous methionines (black circles), and positions of two additional 
methionines present in rDAT (grey circles). Residues pertinent to these studies 
have been selectively numbered (rDAT/hDAT).
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chemical fragmentation reaction requires the protein to be isolated, lacking salts 
and SDS. Thus, a thorough purification procedure was performed in order to 
have suitable samples for this reaction. For the first step, [125I]MFZ 2-24 labeled 
rDAT and hDAT cell lysates were gel purified through SDS-PAGE. The 
radioactive band located between the 66- and the 97- kDa markers was excised, 
rehydrated and subjected to a second purification step by electroelution in order 
to remove DAT from the polyacrylamide gel matrix. Electroeluates were dialyzed 
against MilliQ-filtered distilled water (MilliQ H2O) to remove salts and SDS, and 
the final aqueous sample containing isolated, denatured DATs was evaporated to 
dryness. Labeled rDAT and hDAT samples were treated with or without 1M CNBr 
in 70% formic acid for 24 h in the dark, washed twice and evaporated to dryness, 
followed by SDS-PAGE analysis (Figure 17A). In the absence of CNBr, DATs 
from rat and human origin display their original migration profile at ~80 kDa 
(lanes 1 and 3), while in the presence of CNBr a labeled fragment at ~12 kDa is 
stoichiometrically produced from both isoforms (lanes 2 and 4). This fragment is 
consistent with cleavage at one or more of the TM2 methionines (M106, M111 
and M116) and labeling occurring N-terminal to the cleaved residue (Figure 17B). 
The next potential CNBr site in rDAT is located at position 173 in EL2, and if the 
ligand were attached C-terminal to M116 in rDAT, the labeled fragment would be 
~6 kDa in size; for hDAT the next potential CNBr methionine site is in TM5, at 
position 272, and the size of the labeled fragment would be ~40 kDa (including 
~25 kDa of glycosylation present in EL2). Thus, the presence of the 12 kDa
77
Figure 17.CNBr Hydrolysis of [125I]MFZ 2-24 Labeled rDAT and hDAT. A. hDAT- 
HEK 293 and rDAT-LLCPKi expressing cells were labeled with [125I]MFZ 2-24 
and lysates subjected to purification by SDS-PAGE on a 10% gel. The band 
located between the 66- and the 97-kDa markers was excised, DATs were 
extracted by electroelution and subsequently dialyzed against water, followed by 
evaporation to dryness. Dried DATs were solubilized in 70% formic acid and 
treated with (lanes 2 and 4) and without (lanes 1 and 3) 1M CNBr for 24 h in the 
dark, followed by SDS-PAGE and autoradiography on an 18% gel. B. Schematic 
diagram of DAT highlighting the TMs 1-2 domain labeled by [125I]MFZ 2-24 N- 
terminal to M116 (magenta). Black circles indicate the 13 methionine residues 
common to hDAT and rDAT, and grey circles indicate the positions of the 
additional 2 methionines present in rDAT.
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fragment in both rDAT and hDAT provides additional evidence for the attachment 
of [125I]MFZ 2-24 in the TMs 1-2 domain, N-terminal to M116 (Figure 17B).
Site-directed Mutagenesis, CNBr and Antibody 16 
Analysis of [125I]MFZ 2-24 Labeled hDATs
The CNBr approach proved to be useful in order to determine that 
[125I]MFZ 2-24 attaches to DAT in a domain located N-terminal to M116, which 
includes TM1 and almost all of TM2 (Figure 17B). If the incorporation site lies 
anywhere in the short stretch of amino acids that separates the three 
methionines in TM2, the resolution of the peptide mapping strategy does not 
allow visualization of such a small fragment (<1 kDa). Thus a strategy involving 
site-directed mutagenesis in conjunction with photoaffinity labeling and CNBr 
peptide mapping, was implemented in order to more precisely determine the 
specific [125I]MFZ 2-24 incorporation domain in DAT. Using this method two 
hDAT mutants were generated, one containing a methionine to alanine mutation 
at position 116 (M116A) and another containing simultaneous methionine to 
leucine mutations at positions 111 and 116 (M111L/M116L). hDAT expression 
levels in these mutants were analyzed by western blotting (Figure 18-upper 
panel) and their [125I]MFZ 2-24 photoaffinity labeling pattern (Figure 18-lower 
panel) was proportional to their expression levels. In addition, their functional 
properties were assessed and they exhibited robust cocaine-blockable [3H]DA 
transport and whole cell [3H]CFT binding (Table 4).
For these studies hDAT WT and TM2 mutants were labeled with [125I]MFZ 
2-24 in the presence and absence of cocaine, subsequently gel purified and 
subjected to CNBr digestion, followed by immunoprecipitation with N-terminal
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Figure 18. Expression and Photolabeling of TM1/TM2 Methionine Mutants. HEK 
293 cells stably transfected with hDAT plasmids carrying the indicated mutations 
were photoaffinity labeled with [125I]MFZ 2-24, solubilized in 1% Triton buffer and 
assayed for total protein content. Equal amounts of solubilized protein were 
separated by SDS-PAGE in a 4-20% gel, transferred to a 0.2 pm PVDF 
membrane and blotted with monoclonal anti-hDAT MAB 369 (upper panel). The 
blotted membrane was air-dried and subjected to autoradiography in order to 
visualize the extent of photoaffinity labeling (lower panel).
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Table 4. Kinetic Properties of wild-type and TM1/TM2 Methionine Mutant hDATs. 
Data are presented as mean ± S.E. (n=3). Values were statistically analyzed 
using one-way ANOVA with Tukey’s Multiple Comparison Test.
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Cocaine IC50




p m o l m in '1 m g '1 p m o l m in '1 n M
WT 236.9 ± 13.2 2.54 ± 0.63 866.6 ± 102.7 169.5 ±38.8
M116A 146.2 ± 14.1 0.95 ±0.19 644.5 ±95.1 361.6 ± 15.4*
M111L/M116L 404.7 ± 41.4a 3.71 ±0.56 607.4 ± 76.1 122.6 ± 11.4
L80M/M111L/M116L 47.5 ± 2.9* 2.38 ± 0.69 144.6 ± 21.3a 104.4 ± 10.7
I67M/M111L/M116L 173.6 ± 12.9 2.53 ±0.15 705.2 ± 147.4 129.1 ± 15.2
ap < 0.01, relative to WT values 
b p < 0.001, relative to WT values
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antibody 16, SDS-PAGE and autoradiography. Figure 19 shows the untreated 
(70% formic acid only) samples (odd-numbered lanes) and the CNBr digestion 
(even-numbered lanes) products. Cleavage of the wild type (WT) protein 
generates a cocaine-displaceable labeled fragment that migrates at ~12 kDa as 
previously demonstrated (lanes 2 and 4). Digestion of M116A and M111L/M116L 
hDATs originates cocaine-displaceable labeled fragments with migration patterns 
essentially identical to the ones obtained for WT hDAT (Figure 19, lanes 6, 8, 10, 
12). In addition, all the fragments are immunoprecipitated by antibody 16, 
indicating the presence of the N-terminal epitope. These results verify that 
{125I]MFZ 2-24 attachment occurs N-terminal to M106 (shaded domains in lower 
panels) in hDAT. If the attachment would occur C-terminal to either M111 or 
M106, the labeled CNBr fragment obtained from the M116A and the 
M111L/M116L mutants would contain residues between M111-M272 (~42 kDa) 
and M106-M272 (~43 kDa) respectively, and would be separated from the N- 
terminal epitope. These findings provided additional detailed information 
regarding the attachment site of [125I]MFZ 2-24 in DAT and further validated the 
CNBr mapping strategy, strengthened by the concomitant use with site-directed 
mutagenesis and immunoprecipitation. The elimination of potential CNBr 
cleavage sites allowed for the identification of TM1 and the extracellular-facing 
portion of TM2 as the DAT [125I]MFZ 2-24 labeled region.
Localization of TM1 as the [125I]MFZ 2-24 binding site in DAT 
The use of site-directed mutagenesis combined with CNBr digestion and 
immunoprecipitation is a powerful approach to increase the existing knowledge of
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Figure 19. [125I]MFZ 2-24 Attaches to TMs 1-2 N-terminal to M106. hDAT HEK 
293 cells expressing WT, M116A and M111L./M116L protein were labeled with 
[125I]MFZ 2-24 in the presence or absence of cocaine and subjected to 
purification by SDS-PAGE on a 10% gel. The band located between the 66- and 
the 97 kDa markers was excised, and DATs were extracted by electroelution and 
dialyzed against water, followed by evaporation to dryness. Dried DATs were 
solubilized in 70% formic acid and treated with (lanes 2, 4, 6, 8, 10 and 12) and 
without (lanes 1, 3, 5, 7, 9 and 11) 1M CNBr for 24 h in the dark at room 
temperature. Following digestion, samples were immunoprecipitated with 
antibody 16 and subjected to SDS-PAGE on an 18% gel followed by 
autoradiography. Schematic diagrams of each protein indicate the positions of 
the methionine residues present in them as black circles, with the region of the 
protein corresponding to the labeled fragments shown as magenta shading.
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the incorporation domain in DAT for the cocaine analogue [125I]MFZ 2-24. 
To more precisely determine the exact domain to which this compound becomes 
attached in the TMs 1-2 region in DAT, a series of methionine residues were 
engineered at positions that would allow the production of distinctive fragments 
upon CNBr cleavage. Using site-directed mutagenesis the leucine at position 80 
and the isoleucine at position 67 were individually replaced by methionine in the 
hDAT M111L/M116L mutant such that there would be only one methionine 
(M106) remaining in TM2 and the exogenous methionines would be located in 
TM1 (L80M/M111L/M116L) and the N-terminal tail respectively
(I67M/M111L/M116L). These mutants expressed hDAT protein and incorporated 
[125I]MFZ 2-24 at levels comparable to the WT protein, as demonstrated by 
western blot analysis and photolabeling (Figure 18). Additionally, their functional 
properties were assessed by determining the ICsofor cocaine inhibition of [3H]DA 
transport and whole cell [3H]CFT binding (Table 4).
For these studies WT and TM1/TM2 hDAT mutants (M111L/M116L, 
L80M/M111L/M116L and I67M/M111L/M116L) were photoaffinity labeled with 
[125i]MFZ 2-24, gel purified and digested with CNBr, followed by
immunoprecipitation with N-terminal antibody 16, SDS-PAGE and
autoradiography. Results in Figure 20 show the untreated (70% formic acid only) 
samples (odd-numbered lanes) and the CNBr digestion (even-numbered lanes) 
products. Cleavage of WT and M111L/M116L hDATs generates the previously 
characterized -12 kDa fragment that contains epitope 16 (lanes 2 and 4). 
Importantly, the CNBr digestion product of L80M/M111L/M116L displays faster
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Figure 20. [125I]MFZ 2-24 Attaches to TM 1 Between Residues 67 and 80 . hDAT- 
HEK 293 celis expressing WT, M111L/M116L, L80M/M111L/M116L and 
I67M/M111L/M116L protein were labeled with [125I]MFZ 2-24 and subjected to 
purification by SDS-PAGE on a 10% gel. The band located between the 66- and 
the 97-kDa markers was excised, DATs were extracted by electroelution and 
dialyzed against water, followed by evaporation to dryness. Dried DATs were 
solubilized in 70% formic acid and treated with (lanes 2, 4, 6 and 8) and without 
(lanes 1, 3, 5 and 7) 1M CNBr for 24 h in the dark at room temperature. 
Following digestion, samples were immunoprecipitated with antibody 16 and 
subjected to SDS-PAGE on a 20% gel followed by autoradiography. Schematic 
diagrams of each protein denote the positions of the endogenous and 
engineered methionines as black circles, with the region of the protein 











electrophoretic mobility than the fragments from WT or M111L/M116L proteins 
and migrates at ~9 kDa (lane 6). In addition, this fragment is precipitated with 
antibody 16. This indicates that the labeling occurs N-terminal to L80M (shaded 
region, lower panel) because if the ligand attachment occurred C-terminal to this 
residue the CNBr fragment would extend from L80M to M106 (-3  kDa), would not 
contain the N-terminal epitope, and thus would not immunoprecipitate. The next 
mutant analyzed, I67M/M111L/M116L, produced no precipitable CNBr fragment 
(lane 8). This represents evidence of labeling occurring C-terminal to I67M and 
separation of the N-terminal epitope from the labeled TM1 region (unshaded 
region, lower panel). If the label were incorporated in the cytoplasmic N-terminal 
tail, the fragment would contain the entire tail (-7  kDa) including epitope 16. 
These results indicate that a 13 amino acid stretch of TM1, between residues 67 
and 80, is the site of covalent incorporation in DAT for the cocaine analogue 
[125I]MFZ 2-24.
Photoaffinity Labeling of SERT with [125I]MFZ 2-24 and [125]RTI 82 
The transporter for the neurotransmitter serotonin (5-HT), SERT, belongs 
to the NSSs family and shares high homology with DAT and NET. SERT is a 
well-known target for treatment of mood disorders, such anxiety, depression, and 
post-traumatic stress. Several classes of compounds such as cocaine, the 
tricyclic antidepressants and the serotonin-specific reuptake inhibitors (SSRIs) 
block SERT and inhibit its uptake activity [reviewed in 41]. The cocaine 
analogues [125I]MFZ 2-24 and [125]RTI 82 were used to photoiabel hSERT 
expressing HEK 293 cells in parallel with rDAT expressing LLCPKi celis (Figure
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Figure 21. [125I]MFZ 2-24 and [125]RTI 82 Label SERT. A. rDAT LLCPKi cells and 
hSERT HEK 293 cells were subjected to photolabeling with [125I]MFZ 2-24 and
[125]RTI 82, followed by immunoprecipitation with antibody 16 (against amino 
acids 42-59 in rDAT) or antibody 48 (against amino acids 605-630 in hSERT). B. 
Photoaffinity labeling of hSERT with [125I]MFZ 2-24 displays appropriate 
pharmacological specificity. hSERT FIEK 293 cells were photolabeled with 
[125I]MFZ 2-24 in the presence of the indicated compounds. Photolabeled lysates 
were immunoprecipitated with antibody 48 and subjected to analysis by SDS- 
PAGE and autoradiography [122],
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20). Labeled bands at 70-80 kDa were visible in lysates from both cell lines. 
Immunoprecipitation of lysates with the corresponding anti-DAT (antibody 16) or 
anti-SERT (antibody 48) antibodies specifically pulled down radiolabeled proteins 
(Figure 21 A). The pharmacological specificity of [12i]M FZ 2-24 incorporation into 
SERT was evaluated in the presence of 5-HT reuptake inhibitors followed by 
epitope-specific immunoprecipitation, SDS-PAGE and autoradiography. Covalent 
labeling of SERT was prevented by the SERT blockers (-)-cocaine, citalopram, 
imipramine, and fluoxetine, but not by (+)-cocaine, the DAT inhibitor GBR 12909 
or the NET blocker nisoxetine (Figure 21B) (122]. These results represent the 
first time a photoaffinity approach has been applied for SERT and further 
demonstrate that SERT becomes effectively labeled by [125I]MFZ 2-24 and 
[125I]RTI 82. This strongly suggests that the irreversible incorporation sites on 
DAT and SERT for cocaine analogues are likely to be similar.
Pharmacology of [125I]JHC 2-48 Incorporation to DAT and SERT
The cocaine analogue [125I]JHC 2-48 is a novel photoaffinity ligand that 
contains the cocaine pharmacophore structures present in both [125I]RTI 82 and 
[125I]MFZ 2-24, with the phenyl-iodoazido reactive group appended to the cocaine 
phenyl ring (Figure 11). Synthesis and radioiodination of JHC 2-48 were recently 
described, and evaluation of its kinetic properties revealed high affinity for both 
DAT and SERT [118].
Irreversible incorporation of [125I]JHC 2-48 into hDAT and hSERT was 
analyzed in the presence of cocaine in order to determine the pharmacological 
specificity of the photolabel for these transporters. hDAT or hSERT expressing
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Figure 22. [125I]JHC 2-48 Photoaffinity Labeling of hDAT and hSERT Displays 
Pharmacological Specificity. HEK 293 cells expressing hDAT or hSERT were 
photolabeled with [125I]JHC 2-48 in the presence or absence of (-)-cocaine and 
cells were solubilized. Lysates were subjected to immunoprecipitation with hDAT 






cells were photoiabeled with [125I]JHC 2-48 in the presence or absence of 
(-)-cocaine followed by immunoprecipitation, SDS-PAGE and autoradiography 
(Figure 22). Labeling was prevented when binding was carried out in the 
presence of (-)-cocaine, demonstrating [125I]JHC 2-48 incorporation at a 
pharmacologically significant site in both DAT and SERT.
CNBr Analysis of [125I]JHC 2-48 Labeling in DAT 
The use of CNBr cleavage for the analysis of DAT proteins photoaffinity 
labeled with cocaine analogues has been demonstrated to be a powerful strategy 
to delineate the attachment domains of these compounds [114]. In order to 
initially analyze the incorporation pattern of [125I]JHC 2-48 in DAT, HEK 293 cells 
expressing hDAT were photoiabeled with [125I]JHC 2-48, [125!]MFZ 2-24, and 
[125I]RTI 82 for comparison purposes. Labeled proteins were gel purified, 
digested with CNBr, and analyzed by SDS-PAGE followed by autoradiography 
(Figure 23). Cleavage of [125I]RTI 82 labeled DATs produces the previously 
characterized 6 kDa fragment containing TM6 (lane 2). Similarly, digestion of 
[125I]MFZ 2-24 labeled protein generates the 12 kDa fragment containing TM1 
(lane 4). Interestingly, the digestion product of [125I]JHC 2-48 labeled DATs 
exhibits a pattern distinct from that of the related cocaine analogues (lane 6), with 
absence of any distinguishable labeled fragment, suggesting that this ligand 
becomes incorporated into a region in DAT that has not been previously 
characterized. If TM3 was the attachment site of [125I]JHC 2-48 a ~45 kDa 
labeled fragment originating from cleavage between M116 and M272 should be 
present in the SDS-PAGE analysis of the CNBr fragments, but the absence of
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Figure 23. [125I]JHC 2-48 Incorporates to DAT Distinctively from [125!]RTI 82 and 
[125I]MFZ 2-24. hDAT expressing HEK 293 cells labeled with [125I]JHC 2-48, 
[125I]RTI 82, and [125I]MFZ 2-24 were subjected to purification by SDS-PAGE on a 
10% gel. The band located between the 66- and the 97-kDa markers was 
excised, DATs were extracted by electroelution and dialyzed against water, 
followed by evaporation to dryness. Dried DATs were solubilized in 70% formic 
acid and treated with (lanes 2, 4 and 6) and without (lanes 1, 3 and 5) 1M CNBr 












[125I]RTI 82 [125I]MFZ 2-24 [125I]JHC 2-48
9 9
any discernable labeled fragment in the CNBr map eliminates this possibility. On 
the other hand, there are several methionine residues in the C-terminal half of 
DAT at positions 414, 424 and 427 in TM8, and at positions 569 and 571 in 
TM12 (Figure 16). [125I]JHC 2-48 attachment to a residue within the methionines 
in any of these domains would generate CNBr fragments of 1 kDa or less that 
would not be resolved by the SDS-PAGE method and are consistent with the 
absence of labeled fragments in the initial mapping (Figure 23).
Functional properties of D-147
The GBR series of compounds were originally developed in the early 
1980s and shown to possess high selectivity and affinity for DAT. GBR 12909 
selectively inhibits DA uptake with an IC50 of ~1 nM, and is less potent at NET 
and SERT. This compound exhibits unique neuropharmacological properties, 
including slow dissociation from DAT and the ability to block cocaine self­
administration in non-human primates [123,124], One of the first photoaffinity 
labels developed and used to visualize and characterize DA uptake sites was the 
GBR derivative [125I]DEEP (Figure 24) [125-127], Soon after DAT was cloned, 
[125I]DEEP was used to map GBR binding sites and its attachment was 
localized to the TMs 1-2 domain [110,111],
The photoaffinity label [125I]D-147 is an aryl-dialkyalpiperazine compound 
whose structure derives from GBR 12909. [125I]D-147 is structurally identical to 
[125I]DEEP, except for the position of the phenyl-iodoazido group with respect to 
the piperazine pharmacophore (Figure 24). Synthesis of D-147 was performed by
100
Figure 24. Chemical Structures of GBR-Based Photoaffinity Labels. The structure 
of GBR 12909, an aryl-dialkylpiperazine dopamine uptake blocker, is shown with 
its derivative photoaffinity labels. [125I]DEEP is a piperazine-based photoaffinity 
ligand whose site of incorporation has been identified in TMs 1-2, [125]D-147 is 
the piperazine analogue being characterized in these studies, with a structure 
identical to [125I]DEEP except that the reactive iodo-azido group is placed on the 
biphenyl moiety at the opposite end of the molecule. [125l]AD-96 is a piperidine 





Figure 25. D-147 Binds to DAT with High Affinity. Rat striatal membranes were 
prepared at 10 mg/mL in SP buffer. To initiate the binding competition assay, 
triplicate membrane samples were added to tubes containing 10'1o-10'5 M 
concentrations of D-147 and 1 nM [3H]CFT, followed by a 2 h incubation on ice. 
Membranes were collected and washed three times using a tissue harvester over 
glass fiber filters. Bound radioactivity was quantified by liquid scintillation. The 






Dr. Aloke Dutta (Wayne State University, Ml) and the IC50 value for displacement 
of [3H]CFT binding in rat striatum was found to be 26 nM (Figure 25).
Pharmacology of [125I]D-147 incorporation to DAT 
Irreversible incorporation of [125I]D-147 to rat striatal DATs was assessed 
in the presence of several structurally dverse compounds and the physiological 
substrate DA, in order to determine its pharmacological specificity for DAT. 
Photolabeling was prevented when binding was carried out in the presence of DA 
or the DA uptake inhibitors (-)-cocaine, mazindol, GBR 12909 and nomifensine, 
but was not modified by the inactive enantiomer (+)-cocaine, the NET blocker 
desiDramine or the SERT blocker imipramine (Figure 26). These results 
demonstrate that [125I]D-147 covalently attaches to DAT and that the 
compounds used in these studies are competitive inhibitors and prevent the 
reversible incorporation of the ligand to the transporter. These results support the 
assumption that the irreversible incorporation site for uptake blockers is located 
in or near a pharmacologically significant domain in DAT.
Peptide Mapping of the DAT [125I]D-147 Incorporation Site by Trypsin Proteolysis 
In order to localize the irreversible incorporation site of [125I]D~147 on DAT, 
a tryptic peptide map was performed. [125I]D-147 was used to photoaffinity label 
rat striatal membranes, which were subjected to in situ trypsin proteolysis 
followed by immunoprecipitation with N-terminal antibody 16 and EL2 antibody 5, 
SDS-PAGE separation on a 9-16% gel, and autoradiography (Figure 27). Trypsin 
digestion of [125I]D-147 labeled DATs resulted in a 45 kDa fragment and an
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Figure 26, [125I]D-147 Photoaffinity Labeling Displays DAT Pharmacological 
Specificity. Rat striatal membranes were photolabeled with [125I]D-147 in the 
presence of the indicated compounds [10 pM final concentrations, except 
imipramine (1 pM) and dopamine (100 pM)]. After labeling, samples were 




Figure 27. The GBR Analogue [125I]D-147 Attaches to Distinct Domains in DAT. 
A. Rat striatal membranes were labeled with [125I]D-147, treated with (lanes 2-4 
and 6-8) or without (lanes 1 and 5) increasing concentrations of trypsin and 
subjected to immunopreciphation with antiserum 16 or antiserum 5, followed by 
electrophoresis on a 9-16% gradient gel and autoradiography. Arrows a, b, c and 
d indicate the positions of the [125I]D-147 labeled fragments.
1 0 8
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additional 16 kDa fragment that immunoprecipitate with antibody 16 (lanes 2-4, 
arrows a and b), consistent with incorporation at the TMs 1-2 region. 
Interestingly, precipitation of the same trypsin-digested [125I]D-147 labeled 
sample with antibody 5 isolated a 32 kDa fragment with an additional ~16 kDa 
fragment (lanes 6-8, arrows c and d) consistent with attachment to the TMs 4-6 
domain.
Additionally, the immunological specificity of the [125I]D-147 labeled 
fragments was verified by preabsorbing the antibodies with their respective 
immunizing peptides or non-immunogenic peptides before subjecting the 
samples to immunoprecipitation (Figure 28). Trypsin treated labeled rat striatal 
membranes were immunoprecipitated with antibody 16 alone or antibody 5 
alone, antibody 16 preabsorbed with peptide 16 or antibody 5 preabsorbed with 
peptide 5, and antibody 16 preabsorbed with peptide 5 or antibody 5 
preabsorbed by antibody 16, as indicated. Immunoprecipitation of the 45 kDa 
fragment with serum 16 was prevented by the presence of the antigenic peptide 
but not affected by an unrelated peptide. Precipitation of the 32 kDa fragment by 
antibody 5 was prevented in the presence of the immunizing peptide but 
remained unmodified by an irrelevant peptide.
The relative amount of [125!]D-147 incorporation into DAT appeared to be 
larger for the TMs 4-6 region than for the TMs 1-2 region, as estimated from the 
intensities of the respective 32- and 45-kDa fragments, compared to the full- 
length protein. This suggests an apparently increased incorporation of [125I]D-147 
into the C-terminal half of DAT, similar to [125I]RTI 82.
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Figure 28. Specificity of Immunoprecipitation of [125I]D-147 Labeled Fragments. 
[125I]D-147 labeled rat striatal membranes were subjected to trypsin proteolysis 
and immunoprecipitation with antibody 16 or antibody 5. During the 
immunoprecipitation procedure, samples were supplemented with no peptide, 50 
pg/rnL peptide 16 or 50 pg/rriL peptide 5, as indicated (upper panel). Schematic 
diagram of rDAT showing predicted structure and membrane topology (lower 
panel). Transmembrane (TM) domains are shown as cylinders, the trypsin 
cleavage site on EL2 (R218) is shown as a yellow circle, and antibody epitopes 
are indicated by colored bold lines with numbers. Arrows indicate relationship of 
autoradiograph fragments to domains in schematic DAT. Cleavage of [125;]D-147 
labeled DATs at R218 generated a N-terminal 45 kDa fragment that originated 
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The present results indicate that the [125I]D-147 labeled 45 kDa fragment 
obtained by peptide mapping originates from rDAT N-terminal to the EL2 residue 
R218 and includes TMs 1-3, and the 32 kDa precipitated tryptic fragment is 
derived from rDAT C-terminal to R218 and contains TMs 4-12 (Figure 28). The 
presence of smaller -16 kDa labeled fragments that precipitate with both 
antibody 16 and antibody 5 indicate that [125I]D-147 becomes incorporated into 
both the TMs 1-2 region and the TMs 4-7 region. Thus, in contrast to the closely 
related GBR-like ligand [125I]DEEP that incorporates almost exclusively into TMs 
1-2, the differential positioning of the reactive iodo-azido group in [125I]D-147 




The plasma membrane is an essential component of the cell and functions 
to surround it, determining its boundaries and separating it from the outside 
environment [128]. The membrane consists of prote n molecules embedded in a 
thin double layer of lipids. The protein composition varies in different cell types 
according to their specific functional properties and provides them with exclusive 
characteristics. Transmembrane proteins, including DAT, traverse the lipid 
bilayer and contain portions of their structure on both sides of the membrane. 
They possess amphipathic characteristics, with their hydrophobic regions 
interacting with the lipids and their hydrophilic domains in contact with water at 
both sides of the membrane. Due to their amphipathic structure, common 
methods to study protein tertiary structure such as x-ray crystallography and 
nuclear magnetic resonance (NMR), are extremely complex to execute and 
analyze for these transmembrane proteins. Thus, more indirect biochemical 
techniques have been applied in order to describe DAT’s structural conformation, 
molecular mechanisms, and active sites.
Photoaffinity labeling was initially utilized to visualize dopamine transport 
sites in mammalian tissue before DAT became cloned and characterized 
[125,126], Additionally, the GBR analogue [125]DEEP and the cocaine analogue 
[125]RTI 82 were demonstrated to label the same protein in rat striatal
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preparations, with identical pharmacological profiles [127]. After the cloning of 
DATs in the early 1990s, photoaffinity labeling in combination with peptide 
mapping and epitope-specific immunoprecipitation was used in order to localize 
the binding sites for a variety of structurally diverse DAT inhibitors. [125I]DEEP 
and [125I]RTI 82 were found to attach to TMs 1-2 and TMs 4-7 respectively, 
suggesting the possibility of distinct incorporation sites for different classes of 
uptake biockers [110,111]. Soon after, the incorporation site of the benztropine 
analogue [125I]GA 2-34 was mapped to the TMs 1-2 region, and the GBR 
analogue [125l]AD-96 was demonstrated to attach to both the TMs 1-2 and the 
TMs 4-7 domains [112,113]. The fact that incorporation of numerous structurally 
diverse photoaffinity labels occurs in the same domains suggests that these 
uptake blockers bind to a common pocket on DAT, composed at least partially of 
TMs 1-2 and 4-7, and further that they inhibit transport by a similar mechanism, 
supporting the hypothesis of three-dimensional proximity between the regions 
encompassing TMs 1-2 and TMs 4-7 in the tertiary structure of DAT.
TM1 is a Determinant for Cocaine Binding in DAT 
In this study, using photoaffinity labeling in combination with enzymatic 
and chemical proteolysis, epitope-specific immunoprecipitation, and site-directed 
mutagenesis, the incorporation site on DAT for the novel cocaine analogue 
[125I]MFZ 2-24 was localized to TM1, more specifically to a domain containing 
residues 67 to 80. This represents the first time that the use of photolaboling has 
allowed the positive identification of such a small number of residues as the 
binding site for a cocaine analogue in DAT. The finding that irreversible
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incorporation of [125I]MFZ 2-24 occurs in TM1 strongly suggests that the 
reversible binding site for cocaine is located within this domain, somewhere 
between residues I67 and L80.
The DAT region encompassing TM1 has been extensively studied through 
a variety of approaches due to its high degree of conservation among related 
transporters, and has been implicated in substrate and inhibitor binding through 
several lines of evidence. Studies using DAT-NET chimeras suggested 
interaction of TM1 with cocaine as demonstrated by lower cocaine affinity in 
constructs whose junction points lie in or near this domain [93].
The chemical structure of DA and other DAT substrates, with the 
phenethylamine group positively charged at physiological pH, have led the 
search for charged, aromatic and polar residues as potential targets for 
mutagenesis. TM1 in DAT harbors D79, the first amino acid shown to be 
essential for DAT function. Substitution of this residue to alanine, glycine or 
glutamic acid results in profound losses in DA and cocaine analogue affinities 
[96]. It has been proposed that the carboxyl group of D79 is essential for 
interaction with the positively charged amine from DA, and possibly with the 
tropane nitrogen in cocaine. Importantly, this residue is conserved within the 
related monoamine transporters NET (D75) and SERT (D98), and similar effects 
on substrate uptake have been observed upon amino acid substitution at these 
positions [129], Mutation of rDAT F76, located one helical turn below D79, to 
alanine results in extensive loss of affinity for CFT binding to DAT [97], The 
analogous Y95 in SERT and F72 in NET exhibit reduced substrate and inhibitor
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binding affinities, highlighting the functional importance of this position throughout 
the monoamine transporter family [130,131]. Conversely, mutation of W84 to 
alanine in rDAT and leucine in hDAT leads to increased affinity for the cocaine 
analogue CFT [98,132], Additionally, ionic dependence studies of the W84L 
mutant in hDAT revealed that this mutation contributes to stabilizing the 
transporter on an outward facing conformation, with increased affinity for cocaine 
[98]. Substitution of D68 for asparagine in hDAT led to a significant loss in 
cocaine analogue affinity, but an even greater loss in affinity for a GBR analogue, 
implicating this residue in binding of different classes of inhibitors [133].
The findings from this study using photoaffinity labeling extend and 
complement previous studies that implicate TM1 in cocaine binding, and further 
provide a separate line of biochemical evidence that supports the involvement of 
this domain in the active site of DAT.
Relationship with Bacterial Leucine Transporter (LeuTAa)
The leucine transporter from Aquifex aeolicus (LeuTAa) is the first member 
of the Na7CI'-dependent family of transporters to be crystallized with 
exceptionally high resolution [69]. Although distantly related to DAT (only 20% 
homology) the TMs show high degree of similarity, and a large amount of 
biochemical evidence, including data from photoaffinity labeling studies, supports 
the assumption that DAT adopts a similar three-dimensionai conformation. In 
LeuTAathe binding site for leucine and Na+ is composed mainly of TMs 1, 6, 3 
and 8. Interestingly, TMs 1 and 6 are not continuous helices but contain non­
helical unwound regions that are in direct contact with both substrate and ions. In
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TM1 leucine binding occurs to both sides of the unwound regions at residues 
corresponding to DAT A77, L80 and A81 whereas the Na^ ions are coordinated 
by the carboxyl group of leucine, and LeuTAa A22, N27, G20 and V23, 
corresponding to DAT residues A77, N82, G75, and V78 (Figure 29). All the 
previously described DAT mutations involved in substrate and inhibitor binding 
(D79, F76, W84 and D68) are located within the boundaries of this essential 
region in TM1 and are highly conserved, highlighting their importance in the 
functional aspects of DAT active mechanism. The presence of a glycine in the 
unwound region of TM1 in LeuTAa (G24) and the analogous position of its 
mammalian counterparts, except for the biogenic amine transporters that 
possess an aspartate, may be explained by the structure of the cognate 
substrates. An aspartate at this position may contribute a carboxyl group that 
replaces the one present in amino acid substrates, and could function as a Na+ 
coordination site in addition to directly interact with the amine from the 
substrates.
The findings from these stjdies indicate that the cocaine interaction with 
DAT occurs at residues located within this extremely important and highly 
conserved region, more specifica.ly at a 13-residue stretch located N-terminal to 
the substrate contact point at L80. Although the site for irreversible incorporation 
of the cocaine analogue [125I]MFZ 2-24 to DAT will not likely be identical to the 
residues that directly interact with the cocaine pharmacophore, measurements of 
the interatomic distances between the reactive phenyl-iodo azido group and the
1 1 8
Figure 29. Amino Acid Sequence Alignment of hDAT and LeuT/^. The FASTA 
formatted sequences from LeuTAa (NP_214423) and hDAT (Q01959) were 
aligned using the T-Coffee Multiple Sequence Alignment Tool [134], and 
manually adjusted according to Beuming et al [71]. Colored bars indicate TM 
domains, with amino acids from LeuTAa highlighted in bold letters.
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hDAT 1 MSKSKCSVr-LMSSWAPAKEPNAVGPKEVELlLVKEQNGVQLTSSTLTNPRQSPVEAQDRETW







G K KID FLLSV 1G FAVDLANVWRFPYLCYKNGGGAFLVPY LLFMV1AGMPLFYME LALGQFNRE 
ATRLGLILAMAGNAVGLGNFLRFPVQAAENGGGAFMIPYI IAFLLVGIPLHWIEWAMGR YGGA
TM 3
hDAT 1 2 7  GAAGVWK-ICP----------ILKGVGFTV1LISLYVGFFYNV1IAWALHYLFSSFTTELPWIHCNN
LeuT A a 72 QGHGTTPAIFYLLWRNRFAKILGVFGLWIPLWAIYYVYIESWTLGFAIKFI.VGLVPEPPPNA
hDAT
LeuT A a
1 8 3  SWNSPNCSDAHPGDSSGDSSGLNDTFGTTPAAEYFERGVLHLHQSHGIDDLGPPRWQLTACLV 




2 4 6  I.VIVLLYFSLWKGVKT- SGKW WITATMPYWLTALLLRGVTLP------GAIDGIRAYLSVDFY
174 ITOFI8JVSII.IRGISKGIERFAKIAM PTLFILAVFr.VIRVFLLETPNGTAADGLNFLW TPDFE
TM 6 TM 7
hDAT 304 









PAAVAF FGVANAVA1AKAG- -A FN LGF1TLPA1FSQTAGGTFLGFLW FFLLFFAGLTSSIAIM
TM 9 TM 10
hDAT 4 2 8  ESVITGL1DEFQLI.HRHRELFTLFIVLATFLLSLFCVTNGG1 YVFTLLDHFAAGTS1LFGVL1 
LeuT A a 361  QPM IAFLEOELKL---- SRKHAVXWTAAIVFFSAHLVMFL--NKSLDEMDFWAGTIGVVFFGLT
TM 11
mmmm fmmmmm&mmmamfm
hDAT 4 9 1  EAIGVAWFYGVGQFSDDI QQMTGQRPSLYWRLCWKLVSPCFLLFWWS IVTFRPPHYGAYIF 
LeuT A a 4 1 9  BLZIFFWIFGADKAWEEINRGGI IK VPRi YYYVMRYITPAFLAVLLWWARJEYIPKIMEETH-
TM 12
hDAT 554  
LeuT A a 481
PDWANALGWVIATSSMAMVPIYAAYKFCSLPGSFREKLAYA1APEKDRELVDRGEVRQFTLRH 
- -WTWITRFYIIGLFLFLTFLVFLAERRRNHE3A----------- -------- -------- -
hDAT 6 1 7  WLKV 
LeuT A a ------
1 2 0
essential determinants of cocaine binding will allow more precise identification of 
potential crucial contact points in DAT (Figure 30).
The novel structure provided by the crystallization of this bacterial 
homologue represents a breakthrough in the structure/function studies of this 
family of transporters, and despite being distantly related, the high homology 
found within the TMs demonstrate its importance in serving as a template for 
modeling the mammalian homologues, and complementing the large amount of 
biochemical data that is consistent with this model. However, there are several 
structural aspects that are not shared between LeuTAa and its eukaryotic 
counterparts such as the size of the second extracellular loop that contains the 
glycosylation and disulfide bonds, and the length of the N- and C-terminal tails 
that participate in protein-protein interactions. Perhaps these modifications are 
part of the evolutionary changes that led to their specialized functional properties, 
ionic dependences, and substrate specificity. Additionally, LeuTAa was 
crystallized in a closed conformation, with leucine and ion sites occluded from the 
aqueous environment at both sides of the membrane. The extracellular access 
gate is formed by a small number of amino acids, but the cytoplasmic gate 
consists of highly packed protein structure, with participating residues from TMs 
1,3,6,8 and 10. This stationary structure does not provide information about the 
mechanistic implications of substrate and ion movement across the membrane or 
the inhibition of its function by cocaine and other compounds, leaving this area 
open for future exploration.
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Figure 30. Structures of Cocaine and [125I]MFZ 2-24. A and B. Chemical 
structures of [125I]MFZ 2-24 and cocaine. C. The interatomic distances in 
[125I]MFZ 2-24 between the phenyl- odoazido arm and the tropane nitrogen or 
the phenyl ring are indicated as arrows and obtained from energy minimization 




distance in Angstroms 
N - N3 10.5 
Ph - N3 15.5
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Photolabels with Identical Pharmacophore Exhibit Differential Incorporation 
The irreversible attachment site for [125I]RTI 82 in DAT has recently been 
mapped to TM6 [114], [125I]RTI 82 and [125I]MFZ 2-24 are identical cocaine 
analogues that differ only in the position of the phenyl-iodoazido reactive group 
(Figure 31). Since these compounds share the cocaine pharmacophore with the 
crucial elements for cocaine binding, their reversible binding should be identical, 
with a distinct irreversible incorporation site. The studies presented here 
demonstrate that, in c itrast to [125]RTI 82, [125I]MFZ 2-24 attaches to TM1 in 
hDAT. This is the first time that photolabels harboring identical pharmacophores 
have been shown to exhibit distinct incorporation patterns. In addition, these 
results demons* ate physical proximity of TMs 1 and 6 in the three-dimensional 
arrangement of DAT and are consistent with DAT adopting a conformation 
similar to that of LeuTAa (Figure 31B).
Furthermore, this study strongly supports the idea that multiple domains of 
the DAT primary structure form a binding pocket and are involved in direct 
interaction with cocaine. Although the exact amino acid to which [125I]MFZ 2-24 
becomes attached is not yet identified, this study indicates that incorporation 
occurs within only 13 amino acids in TM1, representing the shortest sequence 
ever identified by photoaffinity labeling techniques.
Analysis of the Incorporation of a Novel Cocaine Analogue to DAT 
The incorporation pattern of the novel cocaine analogue [125I]JHC 2-48, 
the third member of this family of tropane-based DAT inhibitors (Figure 11), was 
found to be different from that of [125I]MFZ 2-24 and [125I]RTI 82 in these
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Figure 31. Photolabels with identical Pharmacophore Attach to Distinct Sites in 
DAT. A. Chemical structures of the cocaine analogues [125I]MFZ 2-24 and 
[125I]RTI 82. They possess identical cocaine pharmacophore but the phenyi- 
iodoazido reactive group is placed in a different position. Schematic diagram of 
DAT indicating the incorporation site for [125I]MFZ 2-24 in TM1 between residues 
I67 and L80 (magenta) and the attachment site for [125!]RTI 82 in TM6 between 
residues 1291 and K336 [108] (blue). B. Schematic diagram of the proposed 
binding pocket for DAT according to LeuTAa [69], showing TMs 1, 6, 3 and 8. 
Cocaine is placed within this pocket, and the attachment sites for [125I]MFZ 2-24 







studies. More in-depth characterization, including site-directed mutagenesis, will 
be necessary in order to localize its attachment domain. However, it is tempting 
to speculate about the potential candidate incorporation domains for [125I]JHC 2- 
48. Based on the positions of the 13 methionine residues in hDAT and the 
preliminary CNBr map of [125I]JHC 2-48 labeled hDAT, the potential domains for 
incorporation of this compound are the regions encompassing TM8 and TM12. 
Three methionines are located at positions 414, 424 and 427 in TM8, and two 
other methionines are situated in TM12 at positions 569 and 572. If incorporation 
of the ligand occurred in a residue located in between the methionines in these 
domains, the resulting CNBr fragments would have masses of 1 kDa or less that 
could not be resolved by the SDS-PAGE method, and are consistent with the 
initial mapping results. In addition, TM8 residues S355 and I359 in LeuTAaare in 
direct contact with the substrate leucine, whiie '.he homologous residues in hDAT 
correspond to S422 and G426 in TM8 and are located between M414 and M427. 
This implicates TM8 as a potential target for further investigation regarding the 
attachment site of [125I]JHC 2-48. Furthermore, mutagenesis and chimeras 
studies have demonstrated the participation of TM8 in ir jortant DAT functions 
involving substrate and inhibitor binding [92, 93, 135]
[125I]D-147 Incorporation Provides Additional Evidence for Proximity of Domains 
The findings from the present studies localize the irreversible incorporation 
site on DAT for the novel GBR analogue [125I]D-147. This compound is 
structurally identical to the previously characterized [125I]DEEP but the phenyl- 
iodoazido reactive group is placed in a different position with respect to the
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piperazine pharmacophore (Figure 24), and becomes incorporated into both 
previously identified labeled regions TMs 1-2 and TMs 4-7. These results 
complement previous findings where the related GBR-based compounds 
[125l]AD-96 and [125I]GA 2-34, attach to one or both of these regions [112,113], 
However, the exact domain to which any of these compounds becomes 
incorporated remains to be explored.
The results of these studies suggest that the irreversible binding domains 
in DAT are shared between structurally diverse uptake blocker analogues, and 
further indicate that these compounds bind to a common binding pocket in the 
transporter composed of various domains. The exact epitopes to which each 
class of inhibitor attaches are not necessarily identical, but are contained within 
the same domains, and further, their differential orientations within the binding 
pocket lead to distinct incorporation patterns. These studies also demonstrate 
that the DAT active site consists of multiple TM domains located distantly in the 
primary structure but proximaily in the three-dimensional conformation of the 
protein. The identification of TM1 as a cocaine binding domain complements the 
finding that indicates TM6 is another component of the cocaine binding site. The 
identical structures of [125I]MFZ 2-24 and [125I]RTI 82 allow their binding to DAT 
with the same spatial orientation in the pocket, and the differential position of the 
reactive group results in irreversible incorporation into discrete domains. This 
strongly indicates that, although distant in the primary structure, TMs 1 and 6 are 
in close three-dimensional proximity and are components, at least partially, of the 
cocaine binding site in DAT. In addition, these studies provide biochemical
1 2 8
evidence that supports the similarity of the three-dimensional arrangement 
between DAT and LeuTAa, with TMs 1 and 6 as partial constituents of the active 
site. Together these results indicate that the substrate and the uptake-blocker 
binding sites may overlap and that these compounds may inhibit dopamine 
transport by competing with the substrate for binding, or by locking DAT in an 
open outwardly conformational state that prevents the necessary movements for 
dopamine to be transported.
1 2 9
§$fmmt~K I M
m A £&v?v ife 'S '' 
k§ .,- >, ■ yiiiriMMiWiMi:
:
W imMm  I r a * *m .
M
B  11I . t ip i
§ P ^ & »
P P lM p
'
.
S fM r - ' ’*  - y * i f f i f x ; j ' * ■  - r j f f f * id y X n r ?  . *' "*
*i»T' '
i  f , ,', j*
f , J ^ \ , i : '  , M*;>;
H §
APPENDIX A
Below is the nucleotide sequence of the 6xHis-hDAT insert. The 6xHistidine tag 
is highlighted in cyan, the EcoRI restriction site is highlighted in grey, the coding 
sequence is underlined, and TM1 is highlighted in bold letters.
5 ' - - - TGCTTACTGG CTTATCGAAA TTAATACGAC TCACTATAGG GAGACCCAAG
CTGGCTAGCG TTTA A A CTTA AGCTTACCAT GGGGGGTTCT H —
101 TATGGCTAGC ATGACTGGTG GACAGCAAAT GGGTCGGGAT
E coR I
CTGTACGACG ATGACGATAA GGTACCTAAG GATCCAGTGT GGTGGAATTC
201 CTCAACTCCC AGTGTGCCCA TGAGTAAGAG CAAATGCTCC GTGGGACTCA
TG TCTTCCGT GGTGGCCCCG GCTAAGGAGC CCAATGCCGT GGGCCCGAAG
301 GAGGTGGAGC TCA TCCTTG T CAAGGAGCAG AACGGAGTGC AGCTCACCAG
CTCCACCCTC ACCAACCCGC GGCAGAGCCC CGTGGAGGCC CAGGATCGGG
401 AGACCTGGGG CAAGAAGATC G ACTTTCTCC t g t c c g t c a t TGGCTTTGCT
GTGGACCTGG CCAACGTCTG GCGGTTCCCC TACCTGTGCT ACAAAAATGG
501 TGGCGGTGCC TTCCTGGTCC CCTACCTGCT CTTCATGGTC ATTGCTGGGA
TG CCACTTTT CTACATGGAG CTGGCCCTCG GCCAGTTCAA CAGGGAAGGG
601 GCCGCTGGTG TCTGGAAGAT CTGCCCCATA CTGAAAGGTG TGGGCTTCAC
GGTCATCCTC ATCTCACTG T A'1’ "TCGGCTT CTTCTACAAC GTCATCATCG
701 CCTGGGCGCT GCACTATCTC TTC TC C TC C T TCACCACGGA GCTCCCCTGG
ATCCACTGCA ACAACTCCTG GAACAGCCCC AACTGCTCGG ATGCCCATCC
801 TGGTGACTCC AGTGGAGACA GCTCGGGCCT CAACGACACT TTTGGGACCA
CACCTGCTGC CGAGTACTTT GAACGTGGCG TGCTGCACCT CCACCAGAGC
901 CATGGCATCG ACGACCTGGG GCCTCCGCGG TGGCAGCTCA CAGCCTGCCT
GGTGCTGGTC ATCGTGCTGC TCTACTTCAG CCTCTGGAAG GGCGTGAAGA
1001 CCTCAGGGAA GGTGGTATGG ATCACAGCCA CCATGCCATA CGTGGTCCTC
ACTGCCCTGC TCCTGCGTGG GGTCACCCTC CCTGGAGCCA TAGACGGCAT
1101 CAGAGCATAC CTGAGCGTTG ACTTCTACCG GCTCTGCGAG GCGTCTGTTT
GGATTGACGC GGCCACCCAG GTGTGCTTCT CCCTGGGCGT GGGGTTCGGG
1201 GTGCTGATCG CCTTCTCCAG CTACAACAAG TTCACCAACA ACTGCTACAG
GGACGCGATT GTCACCACCT CCATCAACTC CCTGACGAGC TTCTCCTCCG
1301 GCTTCGTCGT C TTC T C C TT C CTGGGGTACA TGGCACAGAA GCACAGTGTG
CCCATCGGGG ACGTGGCCAA GGACGGGCCA GGGCTGATCT TCA TCA TCTA
1401 CCCGGAAGCC ATCGCCACGC TCCCTCTG TC CTCAGCCTGG GCCGTGGTCT
TCTTCATCA T GCTGCTCACC CTGGGTATCG ACAGCGCCAT GGGTGGTATG
1501 GAGTCAGTGA TCACCGGGCT CATCGATGAG TTCCAGCTGC TGCACAGACA
CCGTGAGCTC TTCACG CTCT TCATCG TCCT GGCGACCTTC CTCCTG TCCC
1601 TGTTCTGCGT CACCAACGGT GGCATCTACG TCTTCACG CT CCTGGACCAT
TTTGCAGCCG GCACGTCCAT CCTCTTTGGA GTGCTGATCG AAGCCATCGG
1701 AGTGGCCTGG TTCTATGGTG TTGGGCAGTT CAGCGACGAC ATCCAGCAGA
TGACCGGGCA GCGGCCCAGC CTGTACTGGC GGCTGTGCTG GAAGCTGGTC
131
1801 AGCCCCTGCT TTC TC C TG TT CGTGGTCGTG GTCAGCATTG TGACCTTCAG
ACCCCCCCAC TACGGAGCCT A CATCTTCCC CGACTGGGCC AACGCGCTGG
1901 GCTGGGTCAT CGCCACATCC TCCATGGCCA TGGTGCCCAT CTATGCGGCC
TACAAGTTCT GCAGCCTGCC TGGGTCCTTT CGAGAGAAAC TGGCCTACGC
2001 CATTGCACCC GAGAAGGACC GTGAGCTGGT GGACAGAGGG GAGGTGCGCC
ACACGCTCCG CCACTGGCTC AAGGTGTAGA GGGAGCAGAG ACGAAGACCC
2101 CAGGAAGTCA TCCTGCAATG GGAGAGACAC GAACAAACCA AGGAAATCTA




The primers used for site-directed mutagenesis by the QuikChange® method are 
























Shown is the nucleotide sequence of the 6xHis-hDAT insert with the primers 
used for sequencing purposes in bold letters.
T7 promoter -1 (F)
TG CTTA CTG G CTTA TCG AA A TTA ATA CGA C TCA CTA TA G G GAGACCCAAG
CTGGCTAGCG TTT A A A C TT A A G C T TA C C A T G G G G G GTTCT C A T C A T C A T C
A TC A TC A TG G TATGGCTA GC A TG A CTG G TG GACAGCAAAT GGGTCGGGAT
CTGTACGACG ATGACGATAA GGTACCTAAG G A TCCA G TG T G G TG G A A TTC
C T C A A C TC C C A G TG TG CCCA TGAGTAAGAG C A A A TG CTCC GTGGGACTCA
T G T C T T C C G T GG TG GCCCCG GCTAAGGAGC CCA A TG CCG T GGGCCCGAAG
< - hDAT 4 (R)
GAGGTGGAGC T C A T C C T T G T CAAGGAGCAG AACGGAGTGC A G C TCA CCA G
C T C C A C C C T C A CCA A CCCG t u t^AGAGGCC CGTGGAGGCC CAGGATCGGG
AGACCTO. . i GAAGA T C G A C T T T C T C C TG TC C G TC A T T G G C T T T G C T
GiG G A C C T G G C C A A C G TC TG G C G G T TC C C C TA C C T G T G C T ACAAAAATGG
hDAT 2 (F) ->
TGGCGGTGCC T T C C T G G T C C C C T A C C T G C T C T TC A TG G TC A TTGCTGGG A
T G C C A C T T T T CTACA TG GA G C T G G C C C TC G GCCAGTTCAA CAGGGAAGGG
GCCG CTG GTG TCTGG AA GA T CTG CCCCA TA CTGAAAGGTG T G G G C TTC A C
G G TC A TC C T C A T C T C A C T G T A T G T C G G C T T C T TC T A C A A C G T C A TC A TC G
CCTG G G CG CT G C A C T A T C T C T T C T C C T C C T TCACCACGGA G C T C C C C TG G
A TCCA CTG CA A C A A C T C C TG GAACAGCCCC A ACTG CTCG G A T G C C C A T C C
TGG TG A CTCC AGTGGAGACA G C TCG G G CCT CA ACGACACT TTTGGG ACCA
C A C C TG C TG C C G A G T A C T T T GAACGTGGCG T G C TG C A C C T CCA CCAGAGC
< r hDAT 3 (R)
C A TG G CA TCG A CG A CCTG G G GCCTCCG CG G TGGCAGCTCA C A G C C T G C C T
G G TG CTG G TC A T C G T G C T G C T C T A C T T C A G CCTCTGG AA G GGCGTGAAGA
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CCTCAGGGAA GGTG GTA TGG ATCA CA GCCA CCA TG CCATA C G T G G T C C T C
A C TG C C C TG C T C CTG C G TG G G G TC A C C C TC CCTGGAGCCA TAG ACG GCA T
hDAT 3 (F)
CAGAGCATAC CT G A G C G T TG A C T T C T A C C G GCTCTC-CGAG G C G T C T G T T T
GGATTGACGC GG CCACCCA G G T G T G C T T C T C C C TG G G CG T GG GGTTCG GG
GTG CTG A TCG C C T T C T C C A G CTACAACAAG TTCACCAACA A C TG C TA C A G
GGACGCGATT G T C A C C A C C T C C A TC A A C TC CCTG A CGA GC T T C T C C T C C G
G C T TC G TC G T C T T C T C C T T C CTGGGGTACA TGGCACAGAA G CA CA GTGTG
CCCATCGGGG A CGTGGCCAA GGACGGGCCA G G G CTG A TCT T C A T C A T C TA
CCCGGAAGCC A TC G C C A C G C T C C C T C T G T C C TCA G CCTG G G C C G TG G TC T
T C T T C A T C A T G C T G C T C A C C C TG G G TA TCG A CAG CG CCA T GGGTGGTA TG
< r hDAT 2 (R)
GAGTCAGTGA T C A C C G G G C T CA TCG ATGA G T TC C A G C TG C TGCACAGACA
CCG TG A G CTC T TC A C G C T C T T C A T C G T C C T GG CG A CCTTC C T C C T G T C C C
T G TT C TG C G T CACCAA CGG T G G CATCTA CG T C T T C A C G C T C C TG G A C C A T
TTTG CA G CCG G CA C G TC C A T C C TC T T TG G A G T G C TC A TC G AAGCCATCGG
hDAT 4 (F) -»
A GTGGCCTGG T T C T A T G G T G TTG G G C A G TT CAGCGACGAC ATCCAGCAGA
TGACCGGGCA GCG GCCCA GC C T G TA C TG G C G G CTG TG CTG GA A GCTGGTC
A G C C C C T G C T T T C T C C T G T T CGTG G TCG TG G TCA G CA TTG T G A C C TTC A G
A C C C C C C C A C TACG GA GCCT A C A T C T T C C C CGACTGGGCC A A CG CGCTGG
G CTG G G TCA T C G C C A C A TC C TCCATGGCCA TGGTG CCCA T C T A TG C G G C C
TA CA A G TTCT G CA G CCTG CC T G G G T C C T T T CGAGAGAAAC TG G CCTA CG C
C A TTG C A C C C GAGAAGGACC G TG A GCTGG T GGACAGAGGG GAGG TG CGCC
A CA CG CTCCG C C A C TG G C TC AAGGTGTAGA GGGAGCAGAG A CGAAGACCC
<r hDAT 1 (R)
CAGGAAGTCA T C CTG C A A TG GGAGAGACAC GAACAAACCA AGGAAATCTA
A G T T T ----- . 3 '
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